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 The endocrine system is an integral part during development and the regulation 
of various physiological processes in the human body. Dysregulation of the endocrine 
system has frequently been linked to the development of adverse health effects 
including cancer. Man-made chemicals that have the capacity to interfere with the 
endocrine system thereby eliciting adverse health effects (termed endocrine disrupting 
chemicals (EDC)) are therefore of high concern. Available in vitro assays that allow the 
identification and characterization of EDCs mainly provide information on mechanisms 
and pathways of endocrine activity. However, these assays usually do not cover 
functional endpoints that are predictive for adversity such as hormone-related tumor 
formation and progression, necessitating the use of complex in vivo studies that require 
high numbers of test animals.  
This thesis introduces the E-Morph Assay: a novel robust and predictive in vitro 
test method that allows the identification and characterization of chemicals that interfere 
with the estrogen signaling pathway. The development of this assay is based on the 
finding that estrogen signaling modulates the organization of adherens junctions (AJ) in 
the human MCF7 breast cancer cell line. The specificity of this effect to the estrogen 
receptor α (ERα) signaling pathway could be verified by inhibition and knock down 
studies targeting ERα, while modulation of the G-protein-coupled estrogen receptor 1 
(GPER1) did not have any influence. It could further be shown that AJ reorganization is 
mediated by the ERα target gene Amphiregulin (AREG) involving a crosstalk with the 
epidermal growth factor receptor (EGFR) and the downstream RhoA and Src family 
kinase signaling pathways.  
These cancer-related signaling pathways support the mechanistic and clinical 
relevance of AJ organization to be used as a novel functional endpoint in the E-Morph 
Assay for high-content/high-throughput phenotypic screening. The development of a 
96 well plate assay set-up and a pipeline for automated image acquisition and 
quantitative image analysis allows the rapid testing of chemicals at multiple 
concentrations. Pilot screening using a test set of 17 reference chemicals with known 
estrogenic properties demonstrated a high predictive capacity of the E-Morph Assay. 
 In conclusion, the E-Morph Assay will provide a valuable in vitro screening 
method to identify and characterize chemicals with estrogenic activity using estrogen-





 Das endokrine System ist ein zentraler Bestandteil während der Entwicklung 
und sowie der Regulierung physiologischer Prozesse im menschlichen Körper. Eine 
Dysregulation des endokrinen Systems steht in Verbindung mit der Entwicklung 
verschiedener Krankheiten einschließlich Krebs. Vom Menschen hergestellte 
Chemikalien, die in der Lage sind, das endokrine System zu stören und dadurch 
nachteilige Auswirkungen auf die Gesundheit haben (als endokrin wirkende 
Chemikalien (EDC) bezeichnet), geben daher Anlass zur Sorge. Verfügbare in-vitro-
Assays, mit denen EDCs identifiziert und charakterisiert werden können, liefern 
hauptsächlich Informationen über Mechanismen und Wege der endokrinen Aktivität. 
Diese Assays decken jedoch in der Regel keine funktionellen Endpunkte ab, die eine 
Vorhersage zur Krankheitsentwicklung wie hormonbedingte Tumorbildung 
ermöglichen. Daher müssen komplexe in-vivo-Studien durchgeführt werden, für die 
eine große Anzahl von Testtieren erforderlich ist. 
In dieser Arbeit wird der E-Morph-Assay vorgestellt: eine neue robuste und 
prädiktive in-vitro-Testmethode, mit der Chemikalien identifiziert werden können, die 
den Östrogensignalweg stören. Die Entwicklung dieses Assays basiert auf der 
Feststellung, dass der Östrogensignalweg die Organisation von Adherens Junctions (AJ) 
in der menschlichen MCF7 Brustkrebszelllinie verändert. Die Spezifität dieses Effekts 
für den Östrogenrezeptor α (ERα) Signalweg konnte durch Inhibitions- und Knock-
Down-Studien verifiziert werden, während die Modulation des G-Protein-gekoppelten 
Östrogenrezeptors 1 (GPER1) keinen Einfluss hatte. Es konnte gezeigt werden, dass die 
AJ-Reorganisation durch das ERα-Zielgen Amphiregulin (AREG) vermittelt wird. 
Zusätzlich sind der epidermalen Wachstumsfaktor Rezeptor (EGFR) und 
nachgeschaltete Kinase-Signalwege der RhoA- und Src-Familie beteiligt. 
Diese krebsrelevanten Signalwege unterstützen die mechanistische und klinische 
Relevanz der AJ-Organisation als neuen funktionellen Endpunkt im E-Morph-Assay. 
Die Entwicklung einer Pipeline für die automatisierte Bilderfassung und quantitative 
Bildanalyse ermöglicht das schnelle Analysieren von Chemikalien. Das Testen von 17 
Referenzchemikalien mit bekannten östrogenen Eigenschaften zeigte eine hohe 
Vorhersagekapazität des E-Morph-Assays. 
Zusammenfassend stellt das E-Morph-Assay ein wertvolles in-vitro-Assay zur 
Identifizierung von östrogener Chemikalien unter Verwendung östrogenabhängiger 





1.1. Estrogens and the endocrine system 
In the endocrine system, communication between distal organs is mediated by 
circulating signaling molecules, i.e. hormones. The interplay of hormones regulates 
major aspects of development, physiology and behavior. Hormones are synthesized in 
specific glands such as the adrenal or pituitary gland and secreted into the circulatory 
system from where they then act on their target organs.  
1.1.1. Estrogen function and synthesis 
The role of estrogens in the body is diverse. Estrogens are the primary female 
sex hormones and therefore essential for the development and regulation of the female 
reproductive system and secondary sex characteristics. During mammary gland 
development for example they regulate Amphiregulin (AREG) expression, a member of 
the epidermal growth factor family, which binds to the epidermal growth factor 
receptor (EGFR) to promote correct ductal growth and branching [1]. Additionally, 
estrogens play an integral part in other processes in the body e.g. cognitive function or 
bone homeostasis. Research concerning the effect of estrogens on cognitive function 
illustrates the complexity of estrogen signaling. Depending on the neural system 
(hippocampus or striatum), positive as well as negative effects on cognition after 
estrogen administration can be observed [2]. As it was shown that estrogens can 
potentially increase neuron viability and reduce amyloid β accumulation and thus, a 
positive effect of estrogen treatment in Alzheimer disease is currently discussed [3]. 
Additionally, estrogens are the major hormonal regulator of bone homeostasis 
independent of sex. Both activation of bone remodeling and bone resorption are 
inhibited by estrogen action and the loss of estrogen action is connected to an imbalance 
between bone formation and bone resorption with consequences well documented by 
the development osteoporosis in post-menopausal women [4].  
Estrogen synthesis is regulated through the hypothalamic-pituitary-gonadal axis 
(HPG axis). Specific neurons in the hypothalamus secret gonadotropin-releasing 
hormone (GnRH) which stimulates the synthesis of luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) in the anterior pituitary gland. Circulating through 
the blood stream, LH and FSH activate the ovaries to produce testosterone. Testosterone 




main estrogen 17β-estradiol (E2). Estrogens and testosterone in turn influence GnRH, 
LH and FSH secretion through feedback loops. In addition to the synthesis of estrogens 
in the ovaries, estrogens are produced in smaller amount in other tissues such as adipose 
tissue or skin depending on testosterone levels and aromatase expression [5]. Upon 
entry into menopause, ovaries cease to produce estrogens and the alternative tissues 
become the only source for estrogens. For men, these alterative tissues are the only 
source of estrogen. Following synthesis, estrogens are secreted into the blood stream 
where the majority is bound to albumin or sex hormone-binding globulin. The 
non-protein bound estrogens are considered biologically active and can freely diffuse 
through the cell membrane into target cells to initiate estrogen [6]. 
1.1.2. Estrogen signaling 
After passing the cell membrane, estrogens bind to intracellular estrogen 
receptors (ER) and initiate genomic or non-genomic responses. Three main ER have 
been identified so far – ERα, ERβ and the G-protein-coupled ER 1 (GPER1).  
While the potential existence of a specific ER was already proposed by Elwood 
Jensen in the early 1960s [7], the ERα complementary deoxyribonucleic acid (cDNA) 
was only cloned in 1980s, followed by the ERβ ten years later [8]. Both ERα and ERβ 
are ubiquitously expressed but the ratio of ERα and ERβ is tissue dependent. While ERα 
is primarily expressed in the mammary gland, uterus, and vagina, the levels of ERβ are 
higher in ovary, testis, and spleen [9]. Although the genes of ERα (ESR1) and ERβ 
(ESR2) are located on different chromosomes, both receptors show – excluding their 
N-terminal domain – a high degree of sequence homology and similar ligand binding 
affinities. Like the other members of the nuclear steroid hormone receptor superfamily, 
ERα and ERβ contain three basic domains – the N-terminal domain, the DNA binding 
domain, and the ligand binding domain. Transcriptional activity is mediated through the 
two activation function (AF) domains AF-1 and AF-2 located within the N-terminal and 
ligand binding domain of ERα, respectively. While AF-1 is constitutively active, the 
activity of AF-2 is ligand-dependent [10]. ERs primarily localize to the nucleus, with 
only a small percentage found in the cytoplasm or plasma membrane [11].  
In the canonical ER signaling pathway, estrogen binding activates the ERα or 
ERβ by inducing a conformational change and receptor dimerization. Upon activation, 
ER can either directly interact with DNA at palindromic estrogen responsive elements 




protein-1 (SP-1) or activating protein-1 (AP-1) (Figure 1, genomic signaling pathway). 
A portion of the receptor may already reside inside the nucleus to be directly activated 
there [12]. For the transcription initiation, additional cofactors such as steroid receptor 
co-activator-1 (SRC-1) are needed which are recruited by AF-1 or AF-2 in a tissue- and 
receptor-dependent manner. Furthermore, ligand independent ERα activation through 
EGF-mediated phosphorylation of Serine 118 residue has been reported (Figure 1, 
genomic signaling pathway) [9]. Due to their similar structure, ERα and ERβ are able to 
heterodimerize, thereby influencing each other’s signaling activity [8].  
 
Figure 1: Schematic view of the genomic and non-genomic estrogen signaling pathways. 
Estrogen signaling is mediated through the two nuclear estrogen receptors (ER), ERα and ERβ, and the 
G-protein coupled estrogen receptor 1 (GPER1). Upon activation with 17β-estradiol (E2), the ER can act 
as transcription factor and either directly or indirectly through transcription factors (TF) induce gene 
transcription. Ligand-independent ER activation through other signaling pathways is also possible. Non-
genomic responses are mediated by membrane associated ER (mER) and the GPER1, which can 
influence EGFR signaling as well as downstream pathways such as src-family kinases (SFK), mitogen 
activating protein kinase/extracellular signal-regulated kinase (MAPK/ERK) or phospatidyl-inositol-3-
kinase (PI3K) signaling pathway. The red dot indicates phosphorylation.  
 
In addition to the canonical genomic ER signaling pathway, rapid non-genomic 
responses can be induced through cell-membrane-associated ER. Anchored at the cell 
membrane via palmitoylation, membrane-associated ERα are able to transactivate the 
EGFR or influence extracellular signal-regulated kinase (ERK) activity [13, 14]. EGFR 
or ERK activate downstream signaling pathways which in turn influence gene 




The non-genomic signaling route also includes the GPER1, identified only 
recently. The GPER1 belongs to the family of 7-transmembrane spanning G-protein 
coupled receptors (GPCR) and is expressed in numerous tissues e.g. mammary gland, 
cardiovascular system, and bone [15]. Classically, GPCRs are thought to localize at the 
plasma membrane. Though, this appears to be true for GPER1 in some cell types, 
commonly GPER1 seems to be primarily localized in intracellular membranes of e.g. 
the Golgi or endoplasmic reticulum (Figure 1, non-genomic signaling pathway) [11]. 
While the two nuclear ERs ERα and ERβ have comparable ligand binding affinities, the 
binding pocket of the GPER1 is distinct. While E2, the main endogenous estrogen, 
binds to GPER1 with a similar binding affinity as to ERα, Estrone (E1), a slightly 
weaker endogenous estrogen, does not modulate GPER1 activity at all [11]. Notably, 
Tamoxifen (Tam) and Fulvestrant (Fulv), two ERα inhibitors commonly used in the 
treatment of ERα-positive breast cancer, actually activate the GPER1, albeit at lower 
binding affinities [11, 16]. Coupling to heterotrimeric G-proteins, GPER1 can induce 
rapid non-genomic responses. The GPER1 was shown to activate multiple pathways 
like phospatidyl-inositol-3-kinase/Akt (PI3K/Akt) or mitogen activating protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway. Through 
src-family-kinase (SFK)-dependent activation of metalloproteases, GPER1 is also able 
to transactivate EGFR signaling. Additionally, GPER1-mediated activation of the 
adenylyl cyclase and calcium mobilization were reported [11].  
All three ERs contribute to estrogen signal transduction in the various cells and 
tissues of the body. Based on their expression profile, dependence on cofactors and 
cross reactivity, they are able to modulate estrogen signaling in a distinct fashion [11].  
1.1.3. Breast cancer 
Although estrogen signaling has been shown to be required for breast 
development under physiological conditions and has beneficial effects on the neural 
system or bone homeostasis (Section 1.1.1), it also plays a role in the development and 
progression of endocrine-related cancer such as breast cancer [17]. Breast cancer is one 
of the most common cancers worldwide and the most common cancer in women 
independently of the Human Development Index [18, 19]. In Germany, based on the 
incidence rate reported for 2013/2014, one out of eight women is expected to acquire 
breast cancer at some point in their life [20]. The global breast cancer incidence rate has 




women newly diagnosed in 2010. In 2018, around 2.1 million women were diagnosed 
with breast cancer worldwide [21].  
In addition to genetic predisposition or family history, which is primary factor in 
about 10 % of the breast cancer cases, several other factors can contribute to a higher 
breast cancer risk. Reproductive factors, e.g. early onset of menstruation and late first 
pregnancy, or lifestyle factors, e.g. high fat diet and lack of physical activity, are known 
to increase the individual breast cancer risk. Additionally, environmental factors such as 
hormonal contraceptive drugs or hormone replacement therapy during menopause are 
thought to elevate the overall risk [18, 19, 21].  
Generally, breast cancer is categorized according to its histological appearance 
and expression of specific marker proteins. Histologically, breast carcinomas are 
classified according to their origin within the breast (lobule or duct), and their invasion 
status. Four histological subtypes are defined – preinvasive ductal and lobular 
carcinoma in situ, invasive ductal carcinoma no special type, and invasive lobular 
carcinoma [21]. With around 70 %, “invasive ductal carcinoma no special type” (NST) 
is the most common histological subtype [18]. Furthermore, for clinical classification, 
expression of the marker proteins ERα, progesterone receptor (PGR) and human 
epidermal growth factor receptor 2 (HER2) are assessed. The receptor status is decisive 
for later treatment and prognosis. Triple negative (ERα-/PGR-/HER2-) breast cancers 
have for example a generally poor prognosis and are treated by standard chemotherapy 
that targets rather unspecific quickly dividing cells [21]. Over half of the breast 
carcinomas are ERα- and PGR-positive and HER2-negative. If the breast cancer is ERα- 
and/or PGR-positive, endocrine therapy by blocking estrogen signaling has proven to be 
most beneficial. In endocrine therapy, estrogen signaling is generally blocked by 
treating patients with antiestrogens like Tam or inhibiting endogenous estrogen 
synthesis by GnRH analogues in premenopausal women or aromatase inhibitors in 
postmenopausal woman [21]. The antiestrogen Fulv might be used as a second line 
antiestrogen when Tam proves to be ineffective [22]. Adjuvant endocrine therapy is 






1.1.4. Breast cancer at the cellular level 
A connection of estrogen and breast cancer was already recognized at the end of 
the 19
th
 century even before the true nature of cancer was known [23] and is now 
supported by the renown beneficial effects of endocrine therapy as well as strong 
experimental evidence from basic research. Next to a general proliferative effect, 
estrogen signaling is able to influence the expression or activation of marker proteins 
such as E-Cadherin (E-Cad), EGFR or growth factors known to be involved in cancer 
progression. Following, these marker proteins as well as their estrogen dependent 
regulation are described in more detail.  
E-Cadherin and adherens junctions  
In addition to the hormone receptor status, the expression status of the marker 
protein E-Cad is generally assessed and used for the classification into lobular and 
ductal carcinomas. While E-Cad expression is sustained in in situ or invasive ductal 
carcinomas, E-Cad expression is typically lacking in lobular cancer [24]. E-Cad is a 
transmembrane glycoprotein encoded by the tumor suppressor gene CDH1. As essential 
part of adherens junctions (AJ), it plays an important role in cell-cell contact mediation, 
apical-basal cell polarity, and mechanotransduction by connecting to the cellular 
actomyosin network [25]. Additionally, E-Cad interacts with different signal 
transduction pathways, such as EGFR signaling, and promotes contact inhibition of cell 
proliferation [26]. Structurally, E-Cad consists of an extracellular (EC) domain of five 
tandem repeats, a single transmembrane domain, and a cytoplasmic domain. The EC 
domain is responsible for mediating Ca
2+
-dependent homotypic interactions between 
E-Cad proteins of two adjacent cells. Binding of Ca
2+
 induces a conformational change 
in the EC domain which enables interaction with another Ca
2+
 occupied EC domain of 
the neighboring cell [25]. Binding of two E-Cad proteins is rather weak but can be 
strengthened through lateral clustering [27, 28]. The cytoplasmic domain functions as a 
binding platform for several proteins including p120 and β-catenin. β-catenin in turn 
mediates interaction with the actin cytoskeleton through force-dependent binding at 
α-catenin [29].  
E-Cad plays an important role in epithelial-mesenchymal transition (EMT) 
during tissue morphogenesis during in embryonic development but is also implicated in 
cancer progression [30]. Generally, the loss of E-Cad expression is connected with 




recent results also demonstrate a requirement of E-Cad expression for metastases in 
some cancer models [31, 32]. E-Cad expression is mostly dependent on CpG 
dinucleotides methylation, differential promotor activity and regulatory elements in 
exon regions [30]. Estrogen signaling has been shown to directly or indirectly influence 
E-Cad expression in different ways, including activation or inhibition. ERα can directly 
regulate E-Cad expression through binding to the half ERE in the promoter region of 
E-Cad. Whereas ligand-independent ERα binding to the E-Cad ERE was shown to 
induce E-Cad expression, binding of ligand-activated ERα inhibited E-Cad 
expression [33, 34]. Additionally, estrogen was shown to indirectly inhibit E-Cad 
expression by inducing the expression of the transcription factors Slug and Snail, while 
ERα was also shown to indirectly induce E-Cad expression through metastasis 
associated gene protein 3 (MTA3) induction. MTA3 is part of the Mi-2/NuRD 
transcription repression complex, which is a known repressor of Snail 
transcription [32, 35].  
In addition to variable E-Cad expression levels, aberrant localization patterns 
can be observed in some breast cancer samples [24]. The protein levels of E-Cad at cell 
membranes of AJ are normally regulated through an equilibrium of transport to the 
membrane, endocytosis, recycling and degradation [36]. AJ formation and maintenance 
are regulated in part by an interplay of the three Rho family GTPases Rac1, Cdc42 and 
RhoA. While Rac1 and Cdc42 are responsible for AJ formation, RhoA contributes to AJ 
maintenance [27]. Additionally, E-Cad is able to bidirectional interact with the EGFR. 
While E-Cad could inhibit EGFR signaling through NF2/Merlin, EGFR was shown to 
promote E-Cad endocytosis and thereby reduce the pool of functional E-Cad 
protein [26, 36]. 
Epidermal Growth Factor Receptor 
EGFR has been shown to be involved in EMT and promotion of other tumor 
processes such as angiogenesis or metastasis through activating a wide range of 
different signaling pathways. In breast cancer, EGFR overexpression correlates with 
larger tumor size and poor clinical outcome and has been discussed as a potential 
therapeutic target [37]. The sole use of small molecule inhibitors such as Gefitinib in 
breast cancer treatment seemed so far unsuccessful in clinical trials, but the combination 
of endocrine therapy and EGFR inhibition in tamoxifen resistant ERα positive breast 
cancer seems promising at least in animal models [37, 38]. A major problem in breast 




mediated by activation of EGFR signaling, while EGFR inhibition is thought to retain 
Tam responsiveness [38, 39]. 
 EGFR belongs along with HER2, ErbB-3 and ErbB-4 to the ErbB family of 
receptor tyrosine kinases. They consist out of an EC ligand binding domain, a single 
transmembrane domain and a cytoplasmic domain which contains the tyrosine kinase 
domain. The cytoplasmic domain is highly conserved, whereas the EC domain is 
heterogeneous indicating differential ligand binding affinities. Generally, the ErbB 
receptors are activated through binding of growth factors of the EGF family in an 
autocrine or paracrine fashion. Specific ligands for EGFR include EGF, transforming 
growth factor α and AREG [40]. Interaction of the receptor with the ligand causes a 
conformational change within the EC domain which enables dimerization and kinase 
activation. Homo- as well as heterodimers have been described. Next, specific residues 
in the cytoplasmic domain are autophosphorylated and can then serve as docking 
stations for downstream signaling proteins containing a src homology 2 (SH2) domain. 
This way, several signaling pathways, such PI3K/ERK or SFK are activated. SFKs with 
c-src as its most prominent member are one of the longest known oncogenes and have 
been shown to have elevated activity in many breast cancers. Through activating 
cytoplasmic kinases like the focal adhesion kinase (FAK) or specific GTPase activating 
proteins, SFKs influence cell motility and cytoskeleton organization [41, 42]. 
Additionally, SFKs can cause EGFR activation by direct phosphorylation and thus 
modulating EGFR signaling capacity [40].  
As already mentioned, EGFR signaling and estrogen signaling are known to 
crosstalk with each other and a correct interplay of these pathways is essential during 
development, in particular of the mammary gland. Crosstalk can happen through 
various mechanisms. EGFR downstream pathways can influence ERα phosphorylation 
and thus ERα signaling activity and ligand independent ERα dependent gene 
expression [9]. The membrane-associated ER and GPER1 in turn can activate the 
EGFR, either through direct interaction with the receptor or indirectly through SFK-
mediated activation of metalloproteases and the subsequent release of EGF-like growth 
factors [11, 13]. The expression levels of these growth factors are themselves often 
regulated by ERα. A prime example is the EGF family growth factor AREG.  
As mentioned in Section 1.1.1, AREG is essential for correct development of the 
mammary duct and even though additional response elements exist in its promoter 




In mice, knock down of ERα, EGFR or AREG all lead to a similar phenotype in ductal 
malformation [1]. Additionally, AREG was shown to stimulate its own expression 
possibly through EGFR activation as modulation of EGFR activity was shown to 
influence AREG levels [43, 44]. AREG is overexpressed in many types of cancer, 
particularly in breast cancer, and was shown to promote cell proliferation, invasion and 
cancer progression [44]. As it is discussed to play a part in the development of cancer 
resistance, AREG expression comes more into focus as a prognostic marker and 
possible target of cancer therapy [44].  
In conclusion, as breast cancer is the most frequent cancer in women worldwide, 
a lot of research was undertaken to understand the underlying molecular mechanisms 
and possible treatment options. Estrogen and estrogen signaling have long been 
implicated to play a distinct role in the induction and progression of breast cancer. By 
dysregulation of key proteins including E-Cad, EGFR or AREG which are important for 
development and homeostasis of tissues under physiological conditions, estrogen 
signaling influences cancer cell proliferation, progression and metastasis.  
1.2. Endocrine disruption 
Ligand dependent activation of the ER is not limited to endogenous estrogens. 
The discovery of hormones in the beginning of the 20th century was soon followed by 
the discovery and development of chemicals with estrogenic activity for pharmaceutical 
use [45-47]. Tissue extracts used in the earlier years for hormonal treatment were 
substituted with synthesized chemicals [45]. The first contraceptive drug based on a 
mixture of synthetic estrogens and progestogens was introduced in the late fifties [48]. 
Only a few years later, environmental chemicals such as pesticides were also suspected 
to influence the hormonal system and induce adverse health effects in humans and 
wildlife. The US American biologist Rachel Carson for example described in her book 
‘Silent Spring’ the adverse effects of dichlorodiphenyltrichloroethane, dioxin and other 
man-made chemicals on the endocrine system in wildlife populations [45].  
Chemicals responsible for these effects on man and the environment are termed 
endocrine disrupting chemicals (EDC). In 2002, the World Health Organization (WHO) 
defined an EDC as “exogenous substance or mixture that alters function(s) of the 
endocrine system and consequently causes adverse health effects in an intact organism, 
or its progeny, or (sub)population” [49]. Since then, various direct links between 




have been observed [50]. For example, the high amount of reproductive disorders 
observed in polar bears could be attributed to the bioaccumulation of organ halogen 
pollutants [51]. Observed changes in sex ratios of fish correlated with their exposure to 
environmental chemicals through the effluent from sewage plants [50]. These 
observations often led to the ban or stricter regulation of these substances. As we are 
surrounded by a vast number and variety of different man-made chemicals at every 
moment in our life and effects of EDCs highly dependent on the point and duration of 
exposure as well as individual susceptibility and sensitivity [52], direct causal links of 
chemical exposure and endocrine diseases in humans are often difficult to prove yet 
correlations could be found. For example, exposure to polybrominated diphenyl ethers 
is connected to non-descended testes in young males and high exposure to 
polychlorinated dioxins increases the risk of breast cancer [50].  
As a reaction to these discoveries in the nineties, governments including the 
United States of America, Japan, and the European Union put different programs and 
legislations into place in order to identify and eventually ban EDCs. Close to 1000 
chemicals are either known or suspected to have the ability to interfere with the 
endocrine system through binding to hormone receptors or influencing hormone 
metabolism, and some of them can be found nearly ubiquitously [50, 52]. Daily, we 
come into contact with these endocrine active substances (EAS) through common ways 
of exposure (oral, dermal, inhalation) [53], but as indicated by the definition of the 
WHO possible endocrine activity alone does not make an EAS an EDC. Only when 
exposure to an EAS leads to adverse effects through disrupting the endocrine system, 
this substance would be classified as EDC. Classification of a chemical as EDC has 
often great impact on its production and marketing. The European regulations for 
chemicals (REACH (Registration, Evaluation, Authorization and Restriction of 
Chemicals), Regulation (EC) No 1907/2006), biocides (Regulation (EC) No 528/2012) 
and plant protection products (Regulation (EC) No 1107/2009) for example strictly 
impede or prohibit the marketing of chemicals that are classified as EDC in Europe. 
In the following section, different chemical classes with known or suspected 
endocrine disrupting properties are described in more detail. In the final section of the 




1.2.1. Endocrine active/disrupting chemicals 
EAS are structurally diverse and occur in man-made pharmaceuticals 
(e.g. Diethylstilbestrol (DES)) or in plastic products (e.g. Bisphenol A (BPA)) but also 
naturally as mycotoxins in fungi (e.g. Zearalenone (Zea)) or as phytoestrogens in plants 
(e.g. Genistein (Gen) and Daidzein (Dai)). Although a potential endocrine activity of 
specific substances is often easy to identify, it does not necessary mean that the said 
substance acts as an EDC and causes an adverse effect. Following, substances from the 
four mentioned groups are described in more detail.  
Diethylstilbestrol (DES) 
The ‘synthetic estrogen’ DES is one of the first recognized EDCs and a 
prominent example of a link between substance exposure and increased cancer risk in 
humans. After its strong estrogenic capacity has been described by Dodds et al 
in 1938 [46], it was prescribed for pregnant women to reduce the risk of miscarriages 
and abortion in the fifties and sixties [45, 54], even though the benefit of this treatment 
was already controversially discussed at that time [55]. Additionally, it was extensively 
used in the production of livestock to promote growth [56]. In the early seventies, it 
came to light that exposure to DES in utero is associated with a striking increase of a 
rare adenocarcinoma of the vagina in daughters at a young age [57]. Consequently, DES 
was banned for its use on pregnant women and livestock a few years later [56]. 
Follow-up studies revealed other additional adverse endocrine effects in the daughters 
exposed in utreo such as increased risks for breast cancer, preterm delivery or 
infertility [56, 58]. Sons exposed with DES in utero were found to have an increased 
risk of developing genital abnormalities [59]. Studies in mice even indicate possible 
adverse effects in following generations [56, 59]. 
Bisphenol A (BPA) 
While the evidence for endocrine disruption is clear for DES, this is not always 
the case. The classification of bisphenols as EDCs following the WHO definition is a 
point of intense discussion. BPA is particularly in the focus because of its widespread 
usage and high production volume. BPA is essential for the production of polycarbonate 
plastics and epoxy resins, which are used for various consumer products like food 
containers, water pipes or medical equipment [60, 61]. The daily intake of BPA through 
food (the main source of exposure) is estimated to be around 0.48-1.6 µg/kg body 




BPA in the urine of 95 % of a reference population of 394 American adults indicating a 
widespread exposure [62].  
It has already been shown in 1936 that BPA is endocrine-active and exhibits 
estrogenic properties [47, 63]. Since it was recognized that EAS might cause adverse 
health effects, research into possible modes of action of BPA returned into public focus 
and potential endocrine disrupting properties were investigated. BPA was shown to 
elicit, for example, antiandrogen action, and interferes with the thyroid system and 
steroidogenesis [63, 64]. However, correlating BPA exposure to human disease is often 
difficult because of its widespread exposure and thus the lack of control groups as well 
as other confounding factors. Current knowledge points towards adverse health effects 
of BPA including infertility, decreased male sexual function, reduced sperm quality, 
impact on childhood behavior, and cardiovascular diseases, while no correlation was yet 
found between BPA exposure and endometrial disorders or birth weight [65].  
Therefore, the European Union banned the use of BPA in the production of 
infant bottles in 2011 (Regulation (EU) 321/2011) and the European Food Safety 
Authority (EFSA) lowered the tolerable daily intake dose to 4 µg/kg body weight/day 
in 2015 [66]. Due to the ongoing public debate on a possible total ban of BPA, the 
production sector has partly switched to the use of other bisphenols like 
Bisphenol B (BPB) and Bisphenol S (BPS) as BPA alternatives. However, it is not clear 
if such a ban of BPA would be beneficial for human health as the BPA analogues have 
not been investigated as extensively yet and the already existing data suggests that these 
BPA alternatives have at least similar endocrine activity [67, 68]. 
Zearalenone (Zea) 
Zea is an estrogenic mycotoxin produced by Fusarium fungi, common soil fungi 
often found in cereal crops such as corn, maize, barley, or oats. Additionally, Zea is 
added as a food supplement to promote growth of livestock. Human exposure usually 
occurs through consumption of plant products or indirectly through contaminated food 
such as meat or milk [69, 70]. The daily intake of an adult is estimated to range around 
0.0008 to 0.029 µg/kg body weight/day with the provisional maximum tolerable daily 
intake for Zea being set at 0.5 μg/kg body weight by the Joint Committee by the Food 
and Agriculture Organization of the United Nations and WHO (JECFA) [69, 71]. 
 Although Zea exhibits low acute toxicity, it was found to be strongly 
estrogenic [70]. Increased hyperoestrogenism observed in pigs, which ate moldy feed 




and ERβ and influences estrogen signaling. Though its binding affinity is reported to be 
lower than that of endogenous estrogens, it is still in range of the binding affinity of 
phytoestrogens and higher than many potential man-made EDCs [69]. The specific 
binding affinity depends on the isomer and metabolites were found to be more 
estrogenic [72]. In addition to or as a result of hyperoestrogenism, various endocrine 
adverse effects of Zea were observed in vivo including decreased fertility, reduced litter 
size, and changed weight of adrenal, thyroid, testis and pituitary glands [69]. In human, 
several cases of epidemic premature thelarche and precocious puberty suggest an effect 
on puberty timing when exposed to Zea in large amounts but a causal link is hard to 
proof [69]. 
Genistein (Gen) and Daidzein (Dai) 
Plants can be a source for naturally occurring estrogenic substances. Four 
different structural groups of phytoestrogens are known - lignans, prenylflavonoids, 
coumestans and isoflavones. While lignans are primarily found in seeds, fruits and 
vegetables, the primary sources for prenylflavonoids are hops and beer. Coumestan 
levels are high in peas, certain beans, alfalfa and clover sprouts. Food sources with high 
isoflavone concentrations are in particular soy and soy-based products. Because of the 
general switch towards a high soy diet and the usage of soy products in infant food, 
isoflavones are of particular interest [73].  
Similar to Zea, the estrogenic and endocrine disrupting properties of 
phytoestrogens were first observed in livestock. Sheep grazing in isoflavone‐rich red 
clover fields exhibited fertility problems, increased abortion rates and reproductive 
abnormalities. Since then, several cases of isoflavone-related endocrine disruption were 
reported in a multitude of different animals including rodents, birds, fish and cattle [74]. 
Like all the other previously presented EAS, phytoestrogens are able to interact with the 
nuclear ERs but tend to show higher affinity for ERβ [73]. Isoflavones like Dai and Gen 
are additionally thought to influence the steroid and thyroxine biosynthesis, and 
hormone bioavailability [74]. Gen is known to generally inhibit tyrosine kinases 
including the EGFR [75]. While endocrine disruption is clearly observed in animals, 
this is less obvious in humans demonstrating the challenges in dealing with EDCs. 
Asian countries, where soy is part of the normal diet resulting in higher phytoestrogen 
exposure levels, generally see lower incidence rates of cardiovascular diseases and 
breast cancer. Although, many studies were undertaken studying these potential 




consumption of phytoestrogen-containing food is rather beneficial or harmful as it likely 
depends on the susceptibility and sensitivity of the population [73]. Soy is also 
sometimes recommended as an alternative to hormone replacement therapy to lessen 
menopausal symptoms, however the evidence for positive effects is still 
inconclusive [73]. As in vivo experiments in rodents show clear endocrine-related 
defects as a result of phytoestrogen exposure, it cannot be excluded that phytoestrogens 
contribute to estrogen-related adverse health effects. 
Although, all the EAS introduced here are able to bind the ER, the ultimate 
impact on human health is often still controversially discussed. Substances entering the 
body do not only have one mode of action but often can influence many different 
cellular pathways. Additionally, the resulting adverse effects depend on susceptibility to 
exposure, duration and metabolism. Therefore, for a correct classification of EAS many 
different factors need to be considered. 
1.2.2. Chemical regulations and available test methods 
Since the recognition of endocrine disruption through EDCs as a serious health 
issue and establishment of suitable programs and legislations for their regulation, new in 
vitro test methods were developed, and endocrine-related endpoints were integrated into 
existing in vivo assays. Generally, in vitro test methods are rather used for the 
identification of a possible endocrine mode of action and prioritization of chemicals, 
while in vivo assays are able to show an adverse effect. The Organization for Economic 
Cooperation and Development (OECD) has collated available screening assays for 
endocrine-related endpoints in form of the Conceptual Framework for Testing and 
Assessment of EDCs, which is described in OECD Guidance Document (GD) 150 on 
Standardized Test Guidelines for Evaluating Chemicals for Endocrine Disruption [76].  
In this Conceptual Framework, the available assays are sorted according to their 
strength of evidence and complexity. While the methods and assays in level 1 and 2 are 
in silico or in vitro, level 3 to level 5 describe different in vivo studies. In vivo assays are 
generally divided according to the species used, i.e. into mammalian and non-
mammalian studies. 
Level 1 includes an evaluation of already existing data as well as in silico non-
test information like read across, quantitative structure activity relationships, or 
absorption, distribution, metabolism and excretion model predictions. Level 2 contains a 




endocrine modes of action. EDCs can perturb the endocrine systems through various 
mechanisms including receptor binding, transactivation of gene expression or 
influencing hormone biosynthesis and metabolism. Focusing primarily on estrogenic, 
androgenic, thyroidal and steroidogenic (EATS) modalities, different in vitro test 
methods were developed and validated. Available test methods to identify substances 
with estrogenic activity  include the analysis of their ER binding affinity (OECD Test 
Guideline (TG) 493: “Performance-based Test Guideline for Human Recombinant 
Estrogen Receptor (hrER) – In Vitro Assays to Detect Estrogen Receptor Agonists and 
Antagonists” [77]), their ability to modulate ER transactivation (OECD TG 455: 
“Performance-based Test Guideline for Stably Transfected Transactivation – In Vitro 
Assays to Detect Estrogen Receptor Agonists and Antagonists” [78]), and effects on 
estrogen synthesis (OECD TG 456: H295R Steroidogenesis Assay). Level 3 describes 
in vivo assays that are specific for selected endocrine mechanisms including the 
mammalian Uterotrophic Assay (OECD TG 440) and Hershberger Assay (OECD 
TG 441) to detect xenoestrogens and xenoandrogens, respectively, but also include a 
selection of non-mammalian assays including the Short Term Fish Reproductive Assay 
(OECD TG 229). Level 4 and 5 include in vivo studies which provide data on relevant 
adverse effects concerning endocrine-related endpoints. While level 4 studies focus on 
the adverse endocrine effects, level 5 assays provide data concerning an adverse effect 
over a longer time span / life cycle. The Combined Chronic Toxicity/Carcinogenicity 
Studies (OECD TG 451-453) and the Combined 28-Day Reproductive Screening Tests 
(OECD TG 421 and 422) are both examples of level 4 assays while the Two-Generation 
Reproduction Toxicity Study (OECD TG 416) and the Extended One-Generation 
Reproductive Toxicity Study (OECD TG 443) represent level 5 test methods. Nation-
specific regulations and assessment procedures of chemicals build on these different 
methods described in OECD GD 150. 
The protection of humans and wildlife from exposure to EDCs is a central part 
of several regulations in the European Union (EU) including the Plant Protection 
Product Regulation (EU No 1107/2009), the Biocidal Product Regulation 
(EU No 528/2012), the Water Framework Directive (2000/60/EC), REACH 
(EU No 1907/2006), and the Cosmetics Regulation (2009/1223/EC). As 
mentioned (Section 1.2), the classification of a substance as an EDC often triggers its 
exclusion from further use and production. In 2018, the EFSA published a GD on the 




products [79]. In this document, the different assays already described in OECD 
GD 150 are considered as the basis for assessment of potential endocrine effect. They 
are sorted into four groups according to their contribution towards information of 
mechanism and adversity – in vitro mechanistic (Level 2), in vivo mechanistic (level 3 
and selected endpoints of level 4 and 5), EATS-mediated (level 4 and 5, selected level 3 
assays) and sensitive to, but not diagnostic of, EATS (level 4 and 5). Following the 
definition of the WHO, a substance is classified as an EDC when a) it shows an adverse 
effect in an intact organism related to a change in morphology, physiology, growth, 
development, reproduction or life span, b) a endocrine mode of action could be shown, 
and c) it is plausible, that the observed adverse effect is caused through the endocrine 
mode of action. Identification and classification of EDC are conducted based on the 
existing data in a weight-of-evidence approach.  
In the late nineties, the United States (US) Environmental Protection Agency 
(EPA) founded the Endocrine Disruptor Screening Program (EDSP). The Endocrine 
Disruptor Screening and Testing Advisory Committee (EDSTAC) as part of said 
program set up a two-tiered testing strategy. Similar to the Conceptual Framework 
described in OECD GD 150, it divides the same and some additional assays into two 
groups, one providing the mode of action and one showing the adversity. The tier 1 
testing battery contains a selection of in vitro, and simple in vivo assays for mode of 
action identification and prioritization, while the tier 2 testing battery shows the adverse 
effect in vivo using complex animal-intensive studies [80]. 
Currently, over 10,000 unique chemicals are included in the EDSP and in need 
of testing. Completing the tier 1 assays for all chemicals is not feasible as it would 
require decades, a large amount of money and a high number of animals. One chemical 
undergoing the full tier 1 testing battery would mean the sacrifice of about 130 rats, 
30 tadpoles or frogs and 60 fish even before entering tier 2 testing [81]. Similarly, in the 
EU, even though the last deadline for a registration under REACH ended in 2018, it is 
expected that several dossiers will fail at initial evaluation and additional information 
and testing will be required [82]. Due to the high intrinsic animal-to-animal variation of 
some endpoints, many in vivo studies require large group numbers. Additionally, inter-
species differences need to be considered. 
During the last decades, there has been a general drive towards the reduction and 
replacement of animal experiments through the use of alternative non-animal test 




efficient and cost effective. Additionally, they might be more predictive for human 
health effects as many of these alternative test methods are based on human cells. Still 
alternative test methods have the inherent limitation that they cover only specific 
endpoints and do not represent an entire organism. For example, the OECD TG 493 
Estrogen Receptor Binding Assay uses recombinant human ER either full length 
produced in insect cells (Freyberger-Wilson Assay) or only the human ER binding 
domain produced in Escherichia coli (Chemical Evaluation and Research Institute 
(CERI) Assay) [77]. Based on competitive binding between the test chemical in 
comparison to E2, this test method provides information about the ER binding affinity 
of the test chemical but does not consider any functional consequence. Distinction 
between estrogen and antiestrogen action of test substances is possible with the OECD 
TG 455 Estrogen Receptor Transactivation Assay utilizing either Michigan Cancer 
Foundation-7 (MCF7) (VM7-Luc-ER Transactivation (TA) Assay) or human-ERα-
HeLa-9903 (Stably Transfected TA (STTA) Assay) cells that were stably transfected 
with an ERE-regulated luciferase gene [78]. However, as the luciferase expression 
depends on the activation of a rather idealistic ERE, the transactivation assay still does 
not cover more complex modes of ER-dependent transactivation, which would require 
multiple cellular systems with an endogenous ER signaling pathway.  
It is common agreement that the currently available alternative test methods 
alone do not suffice for full replacement of animal tests. The Adverse Outcome 
Pathway (AOP) concept has been introduced by the OECD in 2012 to overcome these 
limitations but also to identify knowledge gaps in toxicologically relevant modes of 
action. AOPs are built on the understanding that a Molecular Initiating Event (MIE) 
leads through a series of Key Events (KEs) across increasing layers of biological 
complexity to an adverse outcome in an organism [83]. The MIE and the KEs can be 
covered by one or multiple alternative test methods but may still also include animal 
testing. Efforts to fully replace animal testing by using AOP-based testing strategies that 
include multiple alternative test methods and fixed data interpretation procedures are 
currently underway. 
Following along the canonical ERα signaling pathway (Section 1.1.2), 
Browne et al, as part of the ToxCast and Tox21 program, developed the ToxCast ER 
model [84]. This model integrates results of 18 different high-throughput screening 
assays to derive a score for ER activity. The assays are selected to follow the mode of 




including ER binding, dimerization and transactivation. Cell proliferation (E-SCREEN 
assay [85]) is included as the only functional endpoint. Comparison with existing data 
from the Uterotrophic Assay (OECD TG 440) showed a high predictive capacity of the 
ER score. The ToxCast ER model is therefore an accepted alternative for the 
Uterotrophic Assay in  the context of Tier 1  substance prioritization [80]. Additionally, 
the ToxCast ER model, with a reduced number of 16 assays, is also a central part of the 
OECD Case Study on the Use of an Integrated Approach to Testing and Assessment 
(IATA) for Identifying Estrogen Receptor Active Chemicals that was published 
in 2019 [86].  
2. Purpose 
We are surrounded by a huge variety of chemicals every day. Some chemicals are 
suspected to disrupt and adversely affect our endocrine system. The endocrine system is 
an integrate part during development and the regulation of most bodily functions. As 
dysregulation of the endocrine system is connected to adverse health effects such as 
cancer, EDC are of high concern. Although several in vitro test methods exist that cover 
the initial events of ER activation only the E-SCREEN assay has a functional endpoint. 
Following the AOP and the drive towards replacement of animal experiments with 
alternative methods, there is a need for new in vitro test methods with functional 
endpoints.  
 The starting point of this thesis was the observation that inhibition of estrogen 
signaling causes AJ reorganization in a human breast cancer cell line. Hence, a first goal 
of this thesis was to further characterize the observed AJ reorganization by studying the 
underlying cellular mechanism and its functional consequences. A second goal was to 
develop a high throughput (HT) compatible alternative test method that uses this AJ 
reorganization as a novel endpoint for the identification of substances with estrogenic 
properties, and to analyze its predictive capacity in comparison to existing data of yet 





3.1. Characterization of adherens junction organization as a novel 
estrogen specific endpoint 
3.1.1. Antiestrogen treatment causes adherens junction reorganization 
Based on the finding that ER signaling modulates AJ organization in 
MCF7/vBOS breast cancer cells [87], the objective of this thesis was to develop a test 
method in a HT compatible assay set-up for the identification of estrogenic substances 
using AJ organization as endpoint.  
As a first step, the ERα responsiveness of MCF7/vBOS cells was verified. 
MCF7/vBOS cells were treated with different concentrations of the estrogen E2 and the 
two antiestrogens Fulv and 4-hydroxytamoxifen (4-OHT) for 48 h. Figure 2 shows the 
resulting effects on gene expression levels of the estrogen-responsive genes TFF1, 
PGR, and EGR3. While E2 treatment did not influence gene expression of the three 
target genes, both antiestrogens caused an inhibition of their expression levels in a dose-
dependent manner and at clinically relevant concentrations of 1 and 10 nM, 
respectively. Even though gene expression was not induced by E2, estrogen signaling 
could be modulated by antiestrogen treatment. The poor responsiveness to ER 
stimulation may be explained by sufficiently high levels of residual estrogens in the cell 
culture medium to fully activate estrogen signaling capacity in MCF7/vBOS cells. The 
high estrogen responsiveness is not surprising since the original MCF7-BOS cells were 
selected for high E2-sensitivity [88]. Notably, the inhibition of target gene expression 
was more pronounced upon Fulv treatment compared to 4-OHT, which agrees with Fulv 
to be a selective ER downregulator (SERD) whereas 4-OHT to acts as selective ER 





Figure 2: Antiestrogens are able to modulate estrogen responsive gene expression.  
Log2 mRNA fold change of TFF1, PGR, and EGR3 of MCF7/vBOS cells treated with different 
concentrations of 17β-estradiol (E2), Fulvestrant (Fulv) or 4-hydroxytamoxifen (4-OHT) for 48 h. qPCR-
data was normalized against YWHAZ as housekeeper and the solvent control (ΔΔCT-method). One dot 
represents one biological replicate, the line indicates the mean and error bars the standard deviation. 
The ER protein disrupting properties of Fulv could be further verified by 
Western blot (Figure 3 a). In line with previously published data [89, 90], treatment 
with Fulv efficiently reduced ERprotein levels while no effect on ESR1 transcription 
was detectable (Figure 3 b). Interestingly, 4-OHT caused an increase in ERα protein but 
not messenger ribonucleic acid (mRNA) levels suggesting that binding of 4-OHT 
stabilized ERα in a post-transcriptional manner (Figure 3 a, b). In order to test if ERα 
signaling can modulate E-Cad expression in MCF7/vBOS cells, the effect of 
antiestrogen treatment on CDH1 mRNA and E-Cad protein expression was analyzed 
(Figure 3 a, b). Treatment with Fulv caused a twofold increase in E-Cad protein levels, 
while no effect on CDH1 mRNA level was detectable suggesting a post-transcriptional 
stabilization of E-Cad. Notably, the increase in E-Cad levels was rather not detectable 
upon 4-OHT treatment, which may be due to the smaller capacity of 4-OHT to inhibit 





Figure 3: Antiestrogen treatment does not cause an increase in E-Cadherin expression but 
adherens junction reorganization.  
a) Protein levels of E-Cadherin (E-Cad) and estrogen receptor α (ERα) after treatment with Fulvestrant 
(Fulv) and 4-Hyrdoxytamoxifen (4-OHT). Protein levels were normalized to the Coomassie blue loading 
control and the solvent control, n= 3. Treatment and Western blot were conducted under supervision by 
Ivana Lazic as part of her master thesis.  b)  Log2 mRNA fold change of MCF7/vBOS cells treated with 
different concentrations of Fulv and 4-OHT for 48 h, normalized as in Figure 2. c) MCF7/vBOS cells 
treated with different antiestrogens (Fulv, 4-OHT, ZK164015, Tamoxifen (Tam)). Cells were stained for 
E-Cad (green) and ERα (magenta), scale bar= 10 µm. 
As a next step, the effect of ERα signaling modulation on AJ organization was 
analyzed by immunofluorescence staining (Figure 3 c). MCF7/vBOS cells were again 
treated with Fulv and 4-OHT and stained for ERα and E-Cad as a marker for AJs. While 
E-Cad uniformly localized across cell membranes (i.e. regular AJs) in the solvent 
control, treatment with Fulv and 4-OHT resulted in the formation of E-Cad clusters and 
AJ reorganization (i.e. irregular AJs). Again, Fulv appeared to be more potent than 




upon 4-OHT treatment. The effect of the two antiestrogens on ERα protein levels 
(see Figure 3 a) was also clearly visible in immunofluorescence staining, when 
comparing the staining intensity of ERα between treatment and the respective solvent 
control. In order to confirm the effect of antiestrogens on AJ organization, two 
additional antiestrogens, the SERD ZK164015 (ZK) and the SERM Tam, the metabolic 
precursor of 4-OHT, were tested. Upon treatment of MCF7/vBOS cells with ZK and 
Tam, the AJs reorganized in a similar fashion as compared to Fulv and 4-OHT. 
Although AJ reorganization upon Fulv and ZK treatment occurred on a similar 
timescale, a 10-fold higher concentration of ZK was required. Tam was the weakest 
antiestrogen. Notably, ZK and Tam also decreased and increased ERα staining intensity, 
respectively, as already seen with Fulv and 4-OHT. Together, these data confirm the 
responsiveness of MCF7/vBOS cells used in this project to the antiestrogen-mediated 
depletion of the ERsignaling pathway in terms of target gene expression and AJ 
organization. 
In order to use AJ organization as endpoint in a test method for the identification 
of estrogenic substances, changes in AJ organization need to be quantifiable. Therefore, 
fluorescence microscopy images needed to be turned into numbers. For this, an image 
analysis pipeline was built using the CellProfiler (CP) and CellProfiler Analyst (CPA) 
open-source software [91, 92]. This pipeline consisted of three main steps – CP-based 
cell segmentation and determination of morphological parameters, and CPA-based cell 
classification (Figure 4 a; see 7.5 for more details). During the classification step, cells 
were categorized into two distinct groups, i.e. regular AJs and irregular AJs, by 
supervised machine learning (training) on control images. The training set of cells was 
then used as a reference for classification of all other images from the same experiment. 
This way, each image could be represented as a number, i.e. the Morphology 
Index (MI). The MI is defined as the fraction of cells showing regular AJs normalized 





Figure 4: Quantification of adherens junction reorganization.  
a) MCF7/vBOS cells were treated with 10 nM Fulvestrant (Fulv) for 48 h and stained for E-Cadherin 
(E-Cad), scale bar= 10 µm. Following, the images were analyzed with a CellProfiler/CellProfiler Analyst 
image analysis pipeline (see main text for details). Cells were segmented (green line) and classified into 
having regular () or irregular adherens junction (AJ) () organization. b) The Morphology Index (MI) 
of MCF7/vBOS cells treated with 10 nM Fulv for 48 h. The MI is defined as the fraction of cells showing 
regular AJ organization normalized to the solvent control. One data point represents the mean of one 
analyzed image. c) The MI of MCF7/vBOS cells treated with different concentrations of Fulv and 
ZK164015. One data point represents the mean of one analyzed image and , ,  the three biological 
replicates. d) Log2 mRNA fold change of TFF1, PGR, und EGR3 of MCF7/vBOS cells treated for 48 h 
with different concentrations Fulv (data from Figure 2) and ZK164015 normalized as in Figure 2. 
 
Treatment of MCF7/vBOS cells with 10 nM Fulv caused a switch from regular 
to irregular AJ organization and thus a decrease of the MI. To test the performance of 
the image analysis pipeline, cells were treated with different concentrations of Fulv and 
ZK, stained for AJs with E-Cad as marker protein and analyzed as described above 
(Figure 4 c). Both antiestrogens caused a decrease of the MI in a dose-dependent 
manner. While Fulv treatment decreased the MI to a mean value of about 0.5 at 1 nM, 
ZK needed a concentration of 100 nM to reach a similar effect level. These differences 




the expression of estrogen-responsive genes (Figure 4 d). Furthermore, the inhibition of 
estrogen-responsive genes correlated well with the reduction of the MI and therefore 
formation of irregular AJs. Additionally, the MI reduction seemed to be a robust read-
out since similar dose-response relationship could be detected in independent 
experiments. Together, these data demonstrate the applicability of the image analysis 
pipeline to accurately detect AJ organization and its usability as an indicator for the 
ERα signaling status in MCF7/vBOS cells. 
Taken together, it was verified, that ERα signaling can be modulated in 
MCF7/vBOS cells by treatment with antiestrogens. Additionally, it was shown that 
inhibition of estrogen signaling caused a reorganization of AJs, which could be 
quantified using a CP/CPA image analysis pipeline. 
3.1.2. Adherens junction reorganization is estrogen receptor α specific 
In order to use AJ organization as endpoint for the identification of estrogenic 
substances, the specificity of Fulv-induced AJ reorganization for the ERα signaling 
pathway needs to be clearly shown. Thus, it was tested whether addition of an estrogen 
such as E2 can prevent Fulv-mediated formation of irregular AJs. MCF7/vBOS cells 
were cotreated with 10 nM Fulv in combination with different concentrations of E2, and 
the MI and estrogen responsive gene expression were analyzed (Figure 5 a, b). With 
increasing E2 concentrations, an increase in the normalized MI was observed. Note that, 
in addition to normalizing the fraction of cells showing regular AJs to the solvent 
control (1.0) as described above, a second normalization to 10 nM Fulv (0) has been 
performed to derive a normalized MI. Hence, Figure 5 a shows that Fulv-mediated AJ 
reorganization was already partially prevented at 0.01 nM E2. At a concentration of 
1 nM E2, the normalized MI value reached the level of the solvent control indicating 
full prevention of AJ reorganization by 10 nM Fulv. The mRNA levels of estrogen 
responsive genes showed a similar trend. Although, an inhibition of estrogen-responsive 
gene expression was still detectable at 0.01 nM E2, mRNA expression levels were 
higher than compared to treatment with 10 nM Fulv alone indicating a partial 
prevention of Fulv-mediated inhibition of ERα signaling. Starting at a concentration of 
0.1 nM E2, estrogen-responsive gene expression reached the level of the solvent 
control. Interestingly, in contrast to cells treated with E2 only (see Figure 2), the mRNA 
levels of PGR even increased over the level of the solvent control at E2 concentrations 




cells under certain circumstances, such as cotreatment with an ERα inhibitor. Together, 
these data points towards ERα dependency of AJ reorganization and illustrate again, 
that the MI can be used as a reliable measure to assess the ERα signaling status of 
MCF7/vBOS cells. 
In order to further pinpoint Fulv-mediated reorganization of AJs to a specific 
inhibition of the ERα signaling pathway, the ERα was directly depleted by silencing 
RNA (siRNA) knock down (KD) targeting ESR1. MCF7/vBOS cells were transfected 
with four different siRNAs individually and in combination for 72 h. To first check for 
KD efficiency, the ESR1 mRNA levels and the ERα protein levels were analyzed 
(Figure 5 c, d). While ESR1 mRNA levels remained unchanged upon Fulv treatment as 
already shown before (see Figure 3 b), its expression was reduced by most individual 
ESR1 siRNAs, except ESR1_10, and their combination (Figure 5 c). A concurrent 
reduction of the estrogen responsive gene TFF1, though less striking as for Fulv, was 
also observed indicating an inhibition of ERα signaling. Combination of the four 
siRNAs led to a strong reduction in ERα protein levels which was comparable to the 
effect of the SERD Fulv. Taken together, the protein and mRNA expression data 
indicate an effective KD of ERα. (Figure 5 d). 
To analyze the effect of ERα KD on AJ organization MCF7/vBOS cells were 
again transfected with the four ESR1 siRNAs individually and in combination for 72 h, 
followed by immunofluorescence staining for E-Cad and ERα (Figure 5 e, f). Image 
analysis was performed as described in Section 3.1.1. The siRNA-mediated KD of ERα 
resulted in an efficient reduction of ERα staining intensity as well as a similar clustering 
of E-Cad and AJ reorganization as previously observed upon Fulv treatment 
(Figure 3 c). Compared to the transfection reagent and scrambled controls, the 
normalized MI decreased significantly upon ERα KD and partly even reached the 
normalized MI level of cells treated with 10 nM Fulv. Together, these data show that 
downregulation of the ERα protein levels is sufficient to induce AJ reorganization and 
thus verify that antiestrogen-mediated reorganization of AJs is specific to inhibition of 






Figure 5: Adherens junction reorganization is prevented by estrogen addition and induced by ERα 
siRNA knock down. 
 a-b) MCF7/vBOS cells were treated with 10 nM Fulvestrant (Fulv) and different concentrations of 
17β-estradiol (E2) for 48 h. a) The normalized Morphology Index (norm. MI) of MCF7/vBOS cells. The 
norm. MI is defined as the fraction of cells showing regular adherens junctions (AJ) normalized to the 
means of solvent control (1.0) and 10 nM Fulv (0). One data point represents the distribution of one 
analyzed image and , ,  the three biological replicates. b) Log2 mRNA fold change of TFF1, PGR, 
and EGR3 normalized as described in Figure 2. c-f) MCF7/vBOS cells transfected with different siRNAs 
targeted against ESR1. c) Log2 mRNA fold change normalized to the corresponding controls as 
described in Figure 2. d) Estrogen receptor α (ERα) protein expression of cells either treated with 
10 nM Fulv or transfected with a mix of ESR1 siRNA. Protein levels were normalized to the Coomassie 
blue loading control and the corresponding control, n= 3. e) Representative images of transfected cells 
(scrambled/ESR1 siRNA) stained for E-Cadherin (green) and ERα (magenta), scale bar= 10 µm. 






Though ERα is the primary target of Fulv and 4-OHT, it was shown that both 
antiestrogens can act on the GPER1. Interestingly, while both compounds act as 
antagonists for ERα, they were shown to act as agonists for the GPER1 and activate its 
downstream signaling cascades [16]. To test for a potential effect of Fulv and 4-OHT on 
GPER1 with regard to AJ reorganization, it was first analyzed whether the specific 
GPER1 agonist G1, which was reported not to act on ERα, would induce AJ 
reorganization. MCF7/vBOS cells were treated with different G1 concentrations alone 
or in combination with 10 nM Fulv, followed by analysis of AJ organization 
(Figure 6 a, b). In the tested concentration range, the normalized MI of G1 alone 
remained close to the solvent control and in combination with 10 nM Fulv around the 
level of the Fulv-treated cells. Higher concentrations could not be tested because of 
cytotoxicity of the substance. Thus, it can be concluded that the GPER1 agonist G1 
does likely not have an effect on AJ organization.  
Next, the effect of the two GPER1 antagonists G36 and G15 on Fulv-mediated 
AJ reorganization was tested. Both have been reported to specifically inhibit GPER1 
induced effects such as PI3K or ERK activation. Whereas G15 has been reported to 
have limited binding affinity to ERα, G36 should be a more specific GPER1 
antagonist [93, 94]. MCF7/vBOS cells were cotreated with either of the two GPER1 
antagonists in combination with 10 nM Fulv, followed by analysis of AJ organization 
(Figure 6 c, d). While upon G36 treatment the normalized MI only slightly increased 
(Figure 6 c), G15 treatment did fully prevent Fulv-induced AJ reorganization at a 
concentration of 5 µM (Figure 6 d).  
As it has been reported that G15 may also act as ERα agonist at high 
concentrations of around 10 µM [93], the effect of G15 and G36 on the expression of 
estrogen responsive genes was further investigated. Interestingly, neither cotreatment 
with G36 nor G15 could prevent the Fulv-mediated inhibition of estrogen responsive 
gene expression (Figure 6 e, f) suggesting that G15 could prevent AJ reorganization 






Figure 6: GPER1 antagonists influence adherens junction organization in contrast to GPER1 
agonists.  
a) Normalized Morphology Index (norm. MI) of cells treated with different concentrations of the GPER1 
agonist G1 with or without 10 nM Fulvestrant (Fulv) for 48 h normalized as described in Figure 5. 
b-c) MCF7/vBOS cells treated with the two GPER1 antagonists G36 or G15 and 10 nM Fulv. b) Norm. 
MI normalized as described in Figure 5. c) Log2 mRNA fold change of TFF1 and PGR normalized as 
described in Figure 2.  
 
To further investigate the G15 effect on Fulv-induced AJ reorganization, 
MCF7/vBOS cells were treated with different Fulv concentrations alone or in 
combination with 5 µM G15, followed by analysis of AJ organization. As expected, 
starting from 1 nM Fulv, the normalized MI decreased in the cells treated with Fulv 
alone with slightly less efficient MI reduction at very high concentrations (Figure 7 a; 
note that the normalized MI was normalized to 10 nM Fulv alone). Treatment of cells 
with different concentrations of Fulv in combination with 5 µM G15 showed again a 
full prevention of AJ reorganization up until 10 nM Fulv. However, starting from 
100 nM Fulv, the mean normalized MI decreased again to a value of around 0.6-0.7 
indicating that higher concentrations of Fulv can at least partially compensate for G15-




concentrations of Fulv, at which the G15-mediated prevention of AJ reorganization 
might be fully compensated, could not be identified, though.  
To test whether G15 could also prevent ERα KD-mediated AJ reorganization, 
MCF7/vBOS cells were transfected with a mixture of four ESR1 siRNAs and treated 
with different concentrations of G15 (Figure 7 b). Transfection of cells with ESR1 
siRNA alone again resulted in a decrease of the normalized MI to about the level of 
Fulv treatment. In contrast to the observed effect of G15 on Fulv treatment, the addition 
of increasing concentrations of G15 to cells transfected with ESR1 siRNA did not 
increase the normalized MI indicating that AJ reorganization was not prevented. To 
control for G15 reactivity in this experiment, cells were also cotreated with 10 nM Fulv 
in combination with different G15 concentrations. While at 5 µM G15 only a slight 
increase of the normalized MI was observed, the normalized MI reached the level of the 
scrambled control at 10 µM G15 indicating that Fulv-mediated AJ reorganization was 
fully prevented. Although G15 was slightly less reactive compared to previous 
experiments (Figure 6 b; Figure 7 a), it still sufficed to analyze the effect of G15 on 
ERα KD-mediated AJ reorganization. The findings that high Fulv concentrations could 
at least partially compensate for G15-mediated prevention of AJ reorganization and the 
lack of an effect of G15 on ERα KD-induced AJ reorganization suggest that G15 may 
interfere at least in part with Fulv through a competitive mechanism.  
In order to address the role of GPER1 for Fulv-induced AJ reorganization more 
directly, MCF7/vBOS cells were transfected with a combination of four different 
siRNAs targeting GPER1 siRNA and treated with 10 nM Fulv (Figure 8 a, b). If Fulv-
induced AJ reorganization depends on the GPER1 activation, the simultaneous KD of 
the GPER1 should at least partially prevent AJ reorganization. However, while GPER1 
KD caused a slight reduction in the normalized MI on its own, the normalized MI of the 







Figure 7: G15 can prevent Fulvestrant-induced adherens junction reorganization but not ERα 
knock down induced.  
a) Normalized Morphology Index (norm. MI) of MCF7/vBOS cells treated with a fixed G15 
concentration and different Fulvestrant (Fulv) concentrations for 48 h normalized as described in 
Figure 5. Treatment of cells and immunofluorescent staining done under supervision by Carolina 
Hurtado during her bachelor thesis. b) Norm. MI of MCF7/vBOS transfected with ESR1 siRNA or 
scrambled and treated with different G15 concentration for 72 h. Cells cotreated with Fulv and G15 were 
included as G15 activity control. The MI was normalized on the scrambled solvent control and Fulv 
otherwise as described in Figure 5. 
To control for GPER1 KD efficiency, GPER1 mRNA levels were analyzed 
(Figure 8 b). In both conditions, GPER1 mRNA level were downregulated by about 
twofold. Interestingly, while the expression of the estrogen responsive gene TFF1 
remained unaffected, the KD of GPER1 caused a slight upregulation of PGR mRNA. 
The previously described Fulv-mediated inhibition of PGR and TFF1 mRNA levels (see 
Figure 4 d) remained however rather unaffected by GPER1 KD. The KD efficiency 
could only be checked on the mRNA level as no suitable antibody could be identified 
for Western blot analysis. Furthermore, MCF7/vBOS cells were transfected with a 
mixture of ESR1 and GPER1 siRNAs separately and in combination (Figure 8 c, d). The 
ERα KD caused the expected decrease of the normalized MI to a level around the Fulv 
positive control, while again no striking effect on AJ reorganization was observed for 
the GPER1 KD. Although, the normalized MI of the cells transfected with both ESR1 
and GPER1 siRNA was slightly increased compared to the Fulv positive control and the 
cells transfected with ESR1 siRNA only, it needs to be noted that the MI was in a 
similar range in previous experiments (see Figure 5 f; Figure 7 b). To control for KD 




ESR1 mRNA levels were decreased by about two-fold in cells transfected with ESR1 
siRNA alone and with both ESR1 and GPER1 siRNA. The corresponding inhibition of 
estrogen responsive gene expression can also be observed. However, the KD effect of 
GPER1 mRNA was less clear as in both KD conditions only a weak downregulation of 
GPER1 was observed. Thus, the influence of GPER1 depletion on ERα KD-induced AJ 
reorganization remained rather unclear in this experiment as the GPER1 KD may 
possibly have not been effective enough. 
 
Figure 8: GPER1 KD does not influence adherens junction organization.  
a-b) MCF7/vBOS cells transfected with a mixture of different GPER1 siRNAs and treated with 10 nM 
Fulvestrant (Fulv) for 72 h. a) The normalized Morphology Index (norm. MI) normalized to the with 
scrambled siRNA transfected cells with or without Fulv treatment otherwise as in Figure 5. b) Log2 
mRNA fold change of GPER1 and estrogen responsive genes TFF1 and PGR normalized on the 
scrambled control otherwise as described in Figure 2. c-d) MCF7/vBOS cells transfected with mixture of 
different GPER1 siRNAs and ESR1 siRNAs, separately and together. c) The norm. MI normalized to the 
cells transfected with scrambled siRNA with or without Fulv treatment otherwise as in Figure 5. d) Log2 
mRNA fold change of GPER1, ESR1 and estrogen responsive genes TFF1 and PGR normalized on the 
scrambled control otherwise as described in Figure 2. 
Taken together, these data show that Fulv-induced AJ reorganization was 
primarily caused by an inhibition of the ERα signaling pathway. This was demonstrated 
by the findings that the addition of an estrogen can prevent Fulv-induced AJ 
reorganization and, more importantly, that the specific depletion of ERα was sufficient 
for AJ reorganization. Although a potential role of the GPER1 signaling pathway in 
Fulv-induced AJ reorganization could not be completely excluded, the data suggests 




3.1.3. Adherens junction reorganization is a relevant functional endpoint 
Changes in cell-cell adhesion play an important role in the development and 
progression of cancer, particularly in epithelial types of cancer such as breast cancer. As 
an inhibition of ERα signaling caused a striking reorganization of AJs in MCF7/vBOS 
breast cancers cells, the underlying molecular mechanisms and functional consequences 
of this reorganization were investigated in more detail. 
Adherens junction reorganization results in increased cell-cell contact stability 
The described reorganization of AJs is characterized by increased clustering of 
E-Cad at the cell membrane. The functional relevance of this E-Cad clustering was 
analyzed using two different assays – the Trypsin Resistance Assay and the quantitative 
Calcium Switch Resilience Assay. The Trypsin Resistance Assay was performed in a 
similar fashion as described in the paper by Shewan et al [95]. The susceptibility of 
E-Cad for Trypsin digestion can be used as a proxy for the fraction of E-Cad that is not 
directly involved in cell-cell contacts. Fulv-treated cells were incubated with 
Trypsin/ethylenediaminetetraacetic acid (EDTA) for 4 min prior to protein lysis and the 
levels of the full length E-Cad protein as well as the resulting fragments were analyzed 
by Western blot (Figure 9 a). Fulv treatment generally caused a slight increase of full 
length (120 kDa) E-Cad protein levels confirming previous observations (Figure 3 a). 
Trypsin treatment resulted in the detection of two additional bands at around 90 kDa 
and 60 kDa. These bands were strikingly less prominent upon Fulv treatment compared 
to solvent control cells indicating a reduced Trypsin susceptibility (Figure 9 a’). Along 
this line, the level of full-length E-Cad did not decrease in Fulv treated cells compared 
to solvent control cells upon Trypsin digestion (Figure 9 a’’). The reduced Trypsin 
susceptibility of Fulv-related cells suggests that an increased fraction of E-Cad was 
involved in cell-cell contact formation, which may be reflected by the clustering of 
E-Cad at the cell membrane.  
In Order to test if the reduced susceptibility of Fulv-treated cells to Trypsin 
digestion and the formation of E-Cad clusters influenced cell-cell contact stability, the 
quantitative Calcium Switch Resilience Assay was performed. In this assay, addition of 
the calcium chelating agent ethylene glycol-bis (β-aminoethyl ether)-N,N,N′,N′-
tetraacetic acid (EGTA) reduces free calcium ions in the medium that are essential for 
E-Cad binding between cells. MCF7/vBOS cells were treated with Fulv as described 




compatible dye CellTrace to visualize the cells. Upon EGTA addition, cells started to 
lose their cell-cell contacts and rounded (Figure 9 b, c). For each captured time point, 
the fraction of rounded cells was determined using an image analysis pipeline that was 
built within the PerkinElmer Harmony high content (HC) analysis software 
(see Section 7.5 for more details). While the fraction of rounded cells immediately 
increased in solvent control cells, in Fulv-treated cells it only started to increase after 
40 min. Even after 120 mins, the fraction of rounded cells in the Fulv treatment 
condition was considerably smaller compared to solvent control cells indicating an 
increased resilience to calcium deprivation.  
 
 
Figure 9: Adherens junction reorganization results in increased cell-cell contact stability.  
a) E-Cadherin (E-Cad) protein level full length and fragments of MCF7/vBOS cells treated with 10 nM 
Fulvestrant (Fulv) and incubated with Trypsin/EGTA solution for 3 min (antibody for intracellular 
domain monoclonal mouse IgG2a, k Anti-E-Cadherin C36). Protein levels were normalized to the 
Coomassie blue loading control and a’) the solvent control incubated with Trypsin or a’’) to the standard 
solvent control, n= 3. b-c) Fulv treated MCF7/vBOS cells were stained with CellTrace and incubated 
with 8 mM EGTA for 120 min. Images were taken every 10 mins and analyzed with the Harmony 
analysis pipeline. Cells were classified into normal (green) and rounded (magenta) cells. 
b) Representative images of the cell classification at different time points, scale bar= 50 µm. c) Fraction 
of rounded cells over time, n= 3.  
Together, the decreased susceptibility to Trypsin digestion and an increased 
resilience to the calcium chelating agent EGTA together suggest that an increased 
fraction of E-Cad was involved in cell-cell contact formation upon Fulv treatment, 




Adherens junction reorganization is regulated by Amphiregulin 
ERα can act directly or indirectly as transcription factor and regulate gene 
expression. As AJ reorganization was caused by ERα signaling inhibition 
(see Section 3.1.2), it was investigated which changes in gene expression correlate with 
the process of AJ reorganization using a time course microarray analysis. This way, 
AREG, a ligand of the EGFR, was identified as a possibly relevant target (data not 
shown). AREG was one of the earliest genes that showed a response to ERα signaling 
inhibition and the protein is known to be essential in breast development (reviewed 
in [1]). Hence, the results from the microarray analysis were verified by performing 
quantitative polymerase chain reaction (qPCR) for the same time points after the start of 
Fulv treatment (Figure 10 a). Whereas ESR1 expression remained unchanged across all 
collected time points, the mRNA levels of the ERα target gene TFF1 started to decrease 
after 24 h. Notably, AREG mRNA levels were already decreased by nearly four-fold 
after 4 h and even by 100-fold after 48 h. To confirm the regulation of AREG expression 
by ERα signaling, MCF7/vBOS cells were either treated for 48 h with different 
concentrations of Fulv alone or cotreated with a fixed concentration of 10 nM Fulv in 
combination with different E2 concentrations (Figure 10 b). With increasing 
concentrations of Fulv, AREG mRNA level decreased in a dose-dependent manner, 
while cotreatment with increasing concentrations of E2 resulted in an increase of AREG 
expression levels. At a concentration of 0.1 nM E2, the Fulv-mediated inhibition of 
AREG expression was fully prevented, which was also the case for the ERα target genes 
as shown before (see Figure 5 b). Interestingly, AREG expression level even increased 
over the level of the solvent control at E2 concentrations of 1 and 10 nM in a similar 
manner as shown for PGR (see Figure 5 b). These data indicate that AREG expression 
levels were very tightly regulated by ERα signaling activity also in our cell system.  
To test whether inhibition of AREG expression is sufficient for AJ 
reorganization, MCF7/vBOS cells were transfected with a combination of four different 
AREG siRNAs for 72 h (Figure 10 c, d). While E-Cad was uniformly distributed across 
cell membranes in the scrambled control, transfection of cells with AREG siRNA 
resulted in an E-Cad distribution similar to Fulv treated cells (Figure 10 c). This 
observation was confirmed across multiple images as the normalized MI of the 
scrambled transfected cells was close to the solvent control, whereas the normalized MI 




depletion of AREG by siRNA appears to be sufficient for the induction of AJ 
reorganization.  
To address the possibility that AREG KD interfered with ERα signaling, thereby 
causing AJ reorganization, the mRNA levels of AREG and TFF1 were compared 
between ERα and AREG KD cells (Figure 10 d). AREG mRNA levels were decreased 
in both KD conditions verifying KD efficiency and ERα-dependency of AREG 
expression. Notably, TFF1 expression was only inhibited in ERα KD cells confirming 
that AREG KD-induced AJ reorganization was not caused by direct interference with 
the ERα signaling pathway. Furthermore, AREG protein levels were reduced in cells 
transfected with AREG or ESR1 siRNA, albeit to a smaller extent than compared to Fulv 
treatment (Figure 10 f).  
As AREG depletion was sufficient to induce AJ reorganization, it was next 
tested whether an AREG overexpression could also prevent the Fulv-induced formation 
of AJ reorganization. MCF7/vBOS cells were transfected with a plasmid encoding for a 
green fluorescent protein (GFP)-tagged human AREG (hAREG-GFP) and then treated 
with 10 nM Fulv. Analysis of AJ organization revealed that the normalized MI of cells 
overexpressing AREG and not treated with Fulv was in the range of the solvent control 
indicating that AJ organization was not affected (Figure 10 g). However, the normalized 
MI of cells overexpressing AREG that were treated with Fulv was considerably 
increased over the level of the Fulv positive control although it did not fully reach the 
level of the solvent control in all three biological replicates. This data shows that 
overexpression of AREG was able to at least partly prevent Fulv-mediated AJ 
reorganization.  
In order to verify that AREG overexpression did not interfere with Fulv-
mediated inhibition of ERα signaling, thereby possibly preventing AJ reorganization, 
mRNA levels of AREG and TFF1 were measured in a single control experiment 
(Figure 10 h). As expected, cells overexpressing AREG showed a striking increase in 
AREG mRNA levels and could fully compensate for Fulv-mediated reduction of AREG 
mRNA levels. Notably, TFF1 mRNA levels were decreased in Fulv-treated cells 
irrespective of AREG overexpression confirming that the partial prevention of AJ 
reorganization was not caused by interference with the Fulv-mediated inhibition of the 
ERα signaling pathway. The expression levels of hAREG-GFP were further analyzed 
by Western blot (Figure 10 i). In line with similar mRNA expression levels, 




solvent control and Fulv-treated cells. Furthermore, a smear of bands was detected right 
above the hAREG-GFP band (70 kDa) suggesting that hAREG-GFP was post-
translationally modified, potentially glycosylated, and therefore correctly processed. 
Interestingly, hAREG-GFP overexpression may have stimulated expression of 
endogenous AREG as the protein level of endogenous AREG (bands at 35 kDa and 
43 kDa) were elevated and their Fulv-mediated reduction was not detectable.  
Taken together, these data clearly show that AREG is an ERα-responsive gene, 
which is in line with previously published data [96-98]. The findings that the KD of 
AREG induced AJ reorganization in a similar fashion as ERα KD or Fulv-treatment but 
without inhibiting ERα signaling, and that the overexpression of AREG at least partly 
prevented Fulv-induced AJ reorganization suggest that ERα signaling controls AJ 





Figure 10: Adherens junction reorganization is depended on Amphiregulin expression.  
a) Log2 mRNA fold change of AREG, ESR1 and TFF1 of MCF7/vBOS cells after different incubation 
times with 10 nM Fulvestrant (Fulv) normalized on solvent control of the corresponding time point 
otherwise as described in Figure 2. b) Log2 mRNA fold change of AREG of MCF7/vBOS cells treated 
with different Fulv concentrations or different concentrations of 17β-estradiol (E2) and 10 nM Fulv 
normalized as described in Figure 2. c-g) MCF7/vBOS cells transfected with a mixture of different 
AREG siRNAs for 72h. c) Representative images of transfected cells (scrambled/AREG siRNA) stained 
for E-Cadherin, scale bar= 10 µm. d) The normalized Morphology Index (norm. MI) normalized as 
described in Figure 5. e) Log2 mRNA fold change of AREG and TFF1 of cells transfected with AREG or 
ESR1 siRNA normalized described in Figure 2. f) Protein expression of cells transfected with a mixture 
of either four ESR1 or AREG siRNA. Protein levels were normalized to the Coomassie blue loading 
control and the scrambled control, n= 3. g-i) MCF7/vBOS transfected with phAREG-GFP to 
overexpress AREG. Cells treated with 10 nM Fulv for 48 h. g) The norm. MI normalized to the 
Fulv-treated or solvent control with six images per replicate, otherwise as in Figure 5. h) Log2 mRNA 
fold change of AREG and TFF1 of cells normalized as described in Figure 2, n= 1. i) Protein expression 




Adherens junction reorganization involves EGFR signaling 
AREG is a known ligand of the EGFR, which regulates in concert with the ERα 
signaling pathway the organization of cells during mammary gland development [1]. To 
test if AJ reorganization also involves the EGFR signaling pathway, EGFR protein and 
mRNA level were analyzed in cells treated with Fulv and 4-OHT (Figure 11 a, b), or 
transfected with ESR1 siRNA or AREG siRNA (Figure 11 c, d). EGFR protein levels 
were strikingly elevated in cells treated with 10 nM Fulv or transfected with ESR1 
siRNA, while a less prominent increase was observed in cells treated with 10 nM 
4-OHT or transfected with AREG siRNA (Figure 11 a, c). Interestingly, this increase in 
protein level was not necessarily reflected by the EGFR mRNA expression levels 
(Figure 11 b, d). Only in ESR1 siRNA cells, the EGFR mRNA level was elevated 
compared to the corresponding control. Treatment with 10 nM Fulv or transfection with 
AREG siRNA rather decreased EGFR mRNA levels, while treatment with 4-OHT did 
not have any effect. Thus, the increase in EGFR protein level upon AJ reorganization 
was likely regulated on a post-transcriptional level potentially involving changes in 
protein stability.  
Considering that AREG is known to activate EGFR signaling and 
downregulation of AREG resulted in AJ reorganization, it was tested whether inhibition 
of EGFR activity alone might be sufficient to induce AJ reorganization. Hence, 
MCF7/vBOS cells were treated with the EGFR inhibitor Gefitinib, a drug that is used in 
breast cancer therapy [37, 38], for 72 h and the effect on AJ organization was analyzed 
(Figure 11 e, f). E-Cad distribution upon treatment with 1 µM Gefitinib was similar to 
that observed for Fulv-treated cells. Quantification of multiple replicates revealed that 
the normalized MI of Gefitinib-treated cells was reduced to a value of around 0.4 
suggesting that inhibition of EGFR signaling activity was sufficient for the induction of 
AJ reorganization, albeit less efficient than inhibition of ERα signaling. However, an 
increase of the Gefitinib concentration did not result in further reduction of the 
normalized MI value. To verify this observation, two additional EGFR inhibitors, 
PD153035 and BIBX1382, were tested (Figure 11 g, h). Both PD153035 and 
BIBX1382 also caused AJ reorganization at a concentration of 1 µM, albeit less 
widespread and striking as compared to Fulv or Gefitinib treatment.  
In order to investigate the possibility that EGFR inhibition interfered with ERα 
signaling, thereby causing AJ reorganization, the mRNA level of the ERα target gene 




reduction of the TFF1 expression level, which was at least not caused by a 
transcriptional depletion of ESR1 (Figure 11 i). Moreover, EGFR and AREG mRNA 
levels were also downregulated in a dose-dependent manner. The similar changes in 
expression through all three inhibitors indicate that the observed effects were specific to 
EGFR signaling inhibition but not off-target effects. Though, AREG was shown to play 
an instructive role in AJ reorganization, the identification of a causal link between 
EGFR inhibition and AJ reorganization requires further studies. Nevertheless, these data 
point towards an essential crosstalk between the EGFR and ERα signaling pathways in 





Figure 11: The EGFR protein level is increased in cells with adherens junction reorganization.  
a,b) MCF7/vBOS cells treated with Fulvestrant (Fulv) and 4-hydroxytamoxifen (4-OHT) for 48 h. 
Protein sampling and Western blot done under supervision by Ivana Lasic as part of her master thesis. 
c,d) MCF7/vBOS cells transfected with a mix of ESR1 or AREG siRNA for 72 h. a,c) Protein expression 
of transfected cells. Protein levels were normalized to the Coomassie blue loading control and the 
corresponding control (solvent control or scrambled), n= 3. b,d) Log2 mRNA fold change of EGFR in 
MCF7/vBOS cells normalized as described in Figure 2. e-h) MCF7/vBOS cells treated with the EGFR 
inhibitors Gefitinib, PD153035 and BIBX1382 for 72 h. e) Representative images of cells treated with 
1 µM Gefitinib stained for E-Cadherin (E-Cad), scale bar= 10 µm. f) Normalized Morphology Index 
(norm. MI) of Gefitinib-treated cells normalized as described in Figure 5. g) Representative images of 
cells treated with 1 µM PD153035 or BIBX1382 stained for E-Cad, scale bar= 10 µm. h) Log2 mRNA 






Inhibition of Src family kinases decreases AREG expression and induces adherens 
junction reorganization 
EGFR is known to regulate and to be regulated by SFK (as reviewed 
in [99], [100]). Additionally, it was reported, that SFKs are an essential mediator of the 
crosstalk between EGFR and ERα [101]. In order to test whether SFKs also play a role 
in AJ organization, MCF7/vBOS cells were treated with three different inhibitors of 
SFKs – kb-src4, PP1, and PP2 (Figure 12 a-d). PP3 was included to control for potential 
side effects on EGFR signaling as reported for the structurally related PP1 and PP2 SFK 
inhibitors. Whereas no effect on AJ organization was observed upon treatment with the 
c-Src specific inhibitor kb-src4, AJ reorganization was induced in cells treated with the 
general SFK inhibitors PP1 and PP2 at 10 µM. Notably, cells treated with 100 µM PP3 
did also show subtle changes in AJ organization, albeit not to the same extent as 
observed for PP1 and PP2, which may be explained by its inhibitory effect on EGFR 
signaling (reported IC50 of 2.7 µM [102]). While the normalized MI of kb-src4-treated 
cells remained close to the normalized MI of the solvent control, the normalized MI of 
PP1- and PP2-treated cells decreased to the level of the Fulv control at 5 µM. 
Interestingly, the normalized MI of PP3-treated cells was rather in the range of the 
solvent control across all concentrations tested indicating that the image analysis 
pipeline was not capable to detect the subtle changes in AJ organization described 
above.  
In order to test whether SFK inhibition also interferes with ERα signaling as 
shown for EGFR inhibition, gene expression of ESR1, TFF1, PGR, and AREG were 
analyzed upon treatment with PP1, PP2, and PP3 (Figure 12 e). All three substances 
showed comparable effects on gene expression levels, which were less pronounced in 
PP3-treated cells. In contrast to all other substances described so far, a slight dose-
dependent increase of ESR1 was observed. Moreover, while TFF1 remained constant, 
PGR expression was induced to a similar extent as shown in Figure 5 b (cotreatment of 
Fulv and E2 with E2 concentrations of 1 and 10 nM). Interestingly, AREG expression 
was considerably downregulated under these conditions. Due to the contradictory 
results of ERα-dependent gene expression, the effect of SFK inhibition on ERα 
signaling remained unclear. These findings underline again the connection of AJ 
reorganization, AREG expression and EGFR activity. However, the role of SFK for AJ 




The inhibitor kb-src4 is reported to be highly specific for c-Src while PP1 and 
PP2 also inhibit other SFKs such as Fyn [103, 104]. As kb-src4 did not cause AJ 
reorganization, which rendered an essential role of c-Src rather unlikely, it was tested 
whether disrupting the function of Fyn influences AJ organization. Hence, cells were 
transfected with a mixture of four FYN siRNA alone or under cotreatment with Fulv for 
72 h (Figure 12 f-g). Under both conditions, FYN mRNA levels were clearly decreased 
in cells transfected with FYN siRNA. Despite the efficient KD of Fyn, no striking effect 
on the normalized MI was observed in untreated Fyn KD cells compared to the 
scrambled solvent control. However, the normalized MI of Fyn KD cells cotreated with 
Fulv was slightly elevated compared to the scrambled Fulv control, which also 
correlated with a slight increase in AREG expression levels.  
To summarize, the SFK inhibitors PP1 and PP2 were able to induce AJ 
reorganization while also causing downregulation of AREG expression levels. Whether 
the downregulation is mediated through ERα signaling inhibition remains to be 
elucidated. The c-Src-specific inhibitor kb-src4 and a Fyn KD however did not cause 
any AJ reorganization while AREG gene expression levels also remained unaffected. 
Since the activity of SFK appears to be directly connected to AREG expression, future 
studies have to unravel the complex interplay of SFK, AREG and EGFR activity in the 





Figure 12: Src family kinase inhibitors PP1 and PP2, but not knock down of Fyn, induced 
adherens junction reorganization. 
a) MCF7/vBOS cells treated with kb-src4 for 144 h. Representative images stained for E-Cad, 
scale bar= 10 µm. b) The normalized Morphology Index (norm. MI) was normalized as described in 
Figure 5, n= 2. Treatment and immunofluorescence staining were conducted under supervision by 
Carolina Hurtado during her bachelor thesis. c-d) MCF7/vBOS cells treated with PP1, PP2, and PP3 for 
48 h. Treatment and immunofluorescent staining was conducted under supervision by Carolina Hurtado 
during her bachelor thesis c) Representative images stained for E-Cad, scale bar = 10 µm. d) Norm. MI 
normalized as described in Figure 5. e) Log2 mRNA fold change of ESR1, TFF1, PGR, and AREG 
normalized as in Figure 2. f-g) MCF7/vBOS cells transfected with a mix of four FYN siRNA for 72 h. 
f) The norm. MI normalized as described in Figure 5. g) Log2 mRNA fold change of AREG and FYN 





Next, it was tested whether substances that can prevent Fulv-induced AJ 
reorganization (see Figure 5 and Figure 6) were also capable of preventing PP1- and 
PP2-induced AJ reorganization. As the effects of PP1 and PP2 on AJ organization and 
gene expression levels were almost indistinguishable, the following experiments were 
performed using the more broadly used PP2 inhibitor only. MCF7/vBOS cells were 
cotreated with 10 µM PP2 and different concentrations of E2, G15, or G36 and the AJ 
organization was analyzed (Figure 13 a, b). The normalized MI of PP2 only treated cells 
was in this experiment slightly higher compared to the Fulv control (Figure 13 a). 
Cotreatment of cells with PP2 and E2 at 0.01 nM or G15 at 5 nM was sufficient to reach 
the normalized MI of the solvent control, while cotreatment with G36 did not fully 
prevent PP2-induced AJ reorganization at any concentration. Although these data 
generally resembled the results of the cotreatment with Fulv (see Section 3.1.2, 
Figure 6), some qualitative differences in the appearance of AJs and E-Cad membrane 
distribution could still be observed (Figure 13 b).   
 
Figure 13: G15 and E2 can partially prevent PP2-induced adherens junction reorganization. 
a) MCF7/vBOS cells cotreated with PP2 and different concentrations of E2, G15 and G36 for 48 h. The 
normalized Morphology Index (norm. MI) normalized as described in Figure 5. b) Representative 
images of MCF7/vBOS cells cotreated PP2 or Fulvestrant (Fulv)  (for the quantification of all replicates 
of the Fulv treated cells see Figure 5 and Figure 6) and different concentrations of E2, G15 and G36 for 





In conclusion, these data indicate that the effect of the SFK inhibitors PP1 and 
PP2 on AJ organization was at least partially mediated by an interplay between the 
SFK, ERα and potentially the EGFR signaling pathways. Although it appears rather 
unlikely that either c-Src or Fyn alone are sufficient for regulating AJ organization, the 
identity of a central SFK member or combination of multiple essential SFK members  
involved in AJ reorganization remain to be identified.   
RhoA activation influences adherens junction reorganization 
SFKs are known to be at the heart of the crosstalk between integrins and the 
Rho-family of small GTPases in adhesion signaling and cytoskeleton rearrangement 
(reviewed in [41]). Thus, a possible role of the Rho-family of small GTPases in AJ 
reorganization was investigated further.  
As a first experiment, it was tested whether RhoA activation affects AJ 
reorganization. MCF7/vBOS cells were pretreated with 10 µM PP2 for 72 h or 
10 nM Fulv for 48 h to induce AJ reorganization (Figure 14 a, b). Subsequently, cells 
were treated for 8 h with different concentrations of the RhoA activator CN03. CN03 is 
acts specifically on RhoA by catalyzing the deamidation of glutamine-63 (Q63), thereby 
blocking GTPase activity and resulting in constitutively active RhoA [105]. Whereas no 
effect of CN03 on AJ organization was observed in the solvent control, CN03 
efficiently reverted the PP2/Fulv-induced AJ reorganization to regular AJ organization. 
Quantification of the AJ organization of Fulv pretreated cells across three replicate 
experiments confirmed these observations as the addition of CN03 for 8 h sufficed to 
raise the normalized MI value of Fulv treated cells to nearly 0.5 (Figure 14 c). These 





Figure 14: RhoA activator CN03 can rescue normal adherens junction organization after 
Fulvestrant or PP2 treatment. 
a) Representative images of MCF7/vBOS cells pretreated with PP2 for 72 h and then cotreated with 
CN03 another 8 h stained for E-Cadherin (E-Cad), scale bar= 10 µm. b-c) MCF7/vBOS cells pretreated 
with Fulvestrant (Fulv) for 48 h and then cotreated with CN03 another 8 h. Treatment and 
immunofulorescence staining was done under supervision by Carolina Hurtado as part of her bachelor 
thesis. b) Representative images of MCF7/vBOS cells stained for E-Cad, scale bar= 10 µm. c) The 
normalized Morphology Index (norm. MI) normalized as described in Figure 5.  
 
As RhoA activation was able to revert PP2/Fulv-induced AJ reorganization, it 
was tested next, whether RhoA inhibition might induce AJ reorganization. Thus, cells 
were treated with the two RhoA inhibitors Y16 and Rhosin at 10 µM and 50 µM for 
48 h and 72 h, respectively (Figure 15 a). While Rhosin binds directly to RhoA to 
generally inhibit RhoA activation (GDP-GTP exchange) by Guanine nucleotide 
exchange factors (GEFs), Y16 only prevents activity of the Rho-specific 
RhoGEF12/Leukemia-associated Rho guanine nucleotide exchange factor 
(LARG) [106, 107]. It needs to be noted that CN03, Y16, and Rhosin are reported to 
also act on the closely related RhoC. Whereas no differences in AJ organization were 
observed between solvent control and Y16-treated cells, E-Cad clusters formed at 10 
µM Rhosin and AJs reorganized at 50 µM Rhosin. To test if Rhosin-mediated AJ 
reorganization can be reverted by CN03 in a similar fashion as shown for PP2 and Fulv, 
MCF7/vBOS cells were pretreated with 50 µM Rhosin for 48 h followed by treatment 
with CN03 for 8 h at 0.5 and 1 µg/ml (Figure 15 b). Treatment with 50 µM Rhosin 
decreased the normalized MI to the level of the Fulv control indicating a similar type of 




Rhosin-treated cells to a level that was similar to the corresponding CN03-treated Fulv 
control indicating a similar mechanism of AJ reorganization. Again, a potential 
interference of RhoA inhibition with the ERα signaling pathway was analyzed by 
measuring the gene expression levels of ESR1, TFF1, and AREG upon treatment with 
Rhosin (Figure 15 c). Though, no changes in the expression of ESR1 were observed, 
both TFF1 and AREG were downregulated suggesting that, similar to the EGFR 
inhibitors (Figure 11 i), AJ reorganization upon RhoA inhibition may also involve ERα 
signaling. In order to test whether Fulv-mediated AJ reorganization may have been 
caused by repression of RHOA expression, the mRNA levels of RHOA and the closely 
related RHOC were analyzed, along with CDH1 whose expression levels were usually 
not affected by any treatment condition (Figure 15 c’). Again, no changes in the mRNA 
levels of CDH1 were observed. Notably, Rhosin treatment resulted in a reduction of 
RHOA and RHOC levels at high concentrations, which was not the case for Fulv-
treatment. Interestingly, RHOC expression levels even increased upon Fulv-treatment, 
while RHOA remained unchanged. Therefore, it was investigated whether modulation 







Figure 15: Inhibition of RhoA through Rhosin induces adherens junction reorganization. 
a) Representative images of MCF7/vBOS cells treated with Y16 and Rhosin for 48 h and 72 h, 
respectively, stained for E-Cadherin (E-Cad), scale bar= 10 µm. b) The normalized Morphology Index 
(norm. MI) of MCF7/vBOS cells pretreated with 50 µM Rhosin or 10 nM Fulvestrant (Fulv) for 48 h 
and then cotreated with CN03 for 8 h normalized as described in Figure 5, n= 2. Treatment and 
immunofulorescence staining was done under supervision by Carolina Hurtado as part of her bachelor 
thesis. c) Log2 mRNA fold change of ESR1, TFF1, and AREG and c’) RHOA, RHOC, and CDH1 of 
MCF7/vBOS cells treated with Rhosin for 72 h normalized as described in Figure 2. Treatment and RNA 
extraction was done under supervision by Carolina Hurtado as part of her bachelor thesis. 
 
To test whether downregulation of RhoA would induce AJ reorganization, 
MCF7/vBOS were transfected with a mixture of four different siRNAs and AJ 
organization and mRNA levels were analyzed (Figure 16 a, b). Although, RHOA was 
efficiently downregulated, its KD neither induced the characteristic AJ reorganization 
nor prevented the effect of Fulv. Analysis of the mRNA levels also demonstrated the 
specificity of the RhoA KD as the RHOC levels remained unchanged. Interestingly, the 
AREG mRNA levels were slightly elevated compared to the corresponding 
untransfected control cells, which closely resembled the results of the Fyn KD 






Next, it was investigated whether overexpression of wild-type (WT) and mutant 
RhoA might influence AJ organization. MCF7/vBOS cells were transfected with 
plasmids encoding for GFP-RhoA
WT
 or two RhoA mutants, the constitutive active 
GFP-RhoA
Q63L
 and the constitutive inactive GFP-RhoA
N19T
. Subsequently, the 
transfected cells were treated with 10 nM Fulv for 48 h and the AJ organization was 
analyzed (Figure 16 c). Neither the overexpression of RhoA
WT
 nor constitutive inactive 
RhoA
N19T
 seemed to influence AJ organization in control or Fulv-treated cells. Notably, 
in line with previous experiments using the RhoA activator CN03 (Figure 14, 
Figure 15 b), Fulv-treated cells overexpressing the constitutive active RhoA
Q63L
 did not 
show AJ reorganization (green arrow), while the surrounding untransfected cells did 
(white arrow). Interestingly, AJ reorganization was also reduced in untransfected cells 
directly connected to several RhoA
Q63L
 overexpressing cells suggesting that neighboring 
cells may influence each other regarding AJ organization.  
To summarize, modulation of RhoA protein levels by KD or overexpression of 
RhoA
WT
 did not influence Fulv-induced AJ reorganization. However, manipulation of 
RhoA activity by expression of mutant RhoA constructs indicates that RhoA was not 
sufficient to induce AJ reorganization but apparently rather played a permissive role as 
the overexpression of the constitutive active mutant RhoA
Q63L
 prevented Fulv-induced 






Figure 16: Overexpression of constitutive active RhoA prevents adherens junction reorganization 
a-b) MCF7/vBOS cells transfected with a mix of RHOA siRNA for 72 h. a) Representative images of 
MCF7/vBOS cells stained for E-Cadherin (E-Cad), scale bar= 10 µm. b) Log2 mRNA fold change of 
AREG, RHOA and RHOC normalized as described in Figure 2. c) Representative images of 






 stained for 
E-Cad, scale bar= 10 µm. White arrow indicates adherens junction (AJ) reorganization; green arrow 
indicates regular AJ organization.  
 
Following, as the RhoA modulators are reported to also act on RhoC and 
quantitative differences in its gene expression levels were observed as described before, 
RhoC was also analyzed in more detail. As a downregulation of the RHOC mRNA level 
was shown upon Rhosin treatment (Figure 15 c), it was tested whether a KD of RHOC 
might induce AJ reorganization. MCF7/vBOS cells were transfected with a mixture of 




was efficiently downregulated, its KD neither induced the characteristic AJ 
reorganization nor clearly prevented the effect of Fulv since the normalized MI of KD 
cells was similar compared to the corresponding controls. Again, the specificity of the 
RhoC KD could be confirmed as the RHOA expression levels remained unchanged 
(Figure 17 b). Notably, in this experiment AREG mRNA levels were rather decreased 
upon RhoC KD when compared to the corresponding control, which is in contrast to the 
increased gene expression levels observed for Fyn KD and RhoA KD. Since an 
upregulation of RHOC was observed upon Fulv treatment, it was further tested whether 
RhoC overexpression might induce or influence AJ reorganization (Figure 17 c). 
MCF7/vBOS cells were transfected with a plasmid encoding for GFP-RhoC
WT
 and 
treated with 10 nM Fulv for 48 h.  Similar to RhoA, no effect of RhoA
WT
 
overexpression on AJ reorganization was observed for Fulv treated or solvent control 
cells.  
 
Figure 17: RhoC expression did not influence adherens junction reorganization. 
a-b) MCF7/vBOS cells transfected with a mix of RHOC siRNA for 72 h. a) The normalized Morphology 
Index (norm. MI) normalized as described in Figure 5. b) Log2 mRNA fold change of AREG, RHOA and 
RHOC normalized as described in Figure 2. c) Representative images of MCF7/vBOS cells transfected 
with RhoA
WT






During development of new cell contacts and cell-cell adhesion, RhoA acts in 
concert with two other members of the Rho family of small GTPases, namely Rac1 and 
Cdc42, both of which are also influenced by SFK signaling (reviewed in [27]). As Rac1 
and Cdc42 are known to negatively influence RhoA activity, it was finally tested 
whether inhibition of these two GTPases might interfere with AJ reorganization. 
MCF7/vBOS cells were treated with three different inhibitors of Rac1 and Cdc42 for 
48 h with or without Fulv (Figure 18). However, none of these inhibitors showed any 
effect on AJ organization in Fulv-treated or control cells at sub-toxic concentrations.  
 
 
Figure 18: Inhibition of Rac1 or Cdc42 does neither induce nor prevent adherens junction 
reorganization. 
Representative images of MCF7/vBOS cells treated with Rac inhibitor I, Rac1 inhibitor II and Rac1-
Cdc42 inhibitor with or without 10 nM Fulvestrant (Fulv) in the background for 48 h stained for 
E-Cadherin (E-Cad), scale bar= 10 µm. 
 
Taken together, though RhoA activation through CN03 cotreatment or 
overexpression of the constitutive active mutant GFP-RhoA
Q63L
 was able to revert or 
prevent AJ reorganization, it did not play an instructive role in Fulv-induced AJ 
reorganization. As RhoA is a major hub in cytoskeleton regulation, its activation might 
just cause general changes in the regulation of the cytoskeleton. While the RhoA 
inhibitor Rhosin did induce AJ reorganization, it also downregulated AREG and 
inhibited ERα responsive gene expression. The protein expression levels of RhoA and 
RhoC per se did not appear to influence AJ reorganization. Therefore, the specific role 
of Rho family GTPases for AJ organization remains to be addressed in more detail in 





3.2. Development of a high throughput compatible assay set-up 
In addition to the investigation of the underlying mechanism for AJ 
reorganization, a main objective of this thesis was the development of an 
HT-compatible assay set-up for the identification of estrogenic substances using AJ 
reorganization as the endpoint. A useful HT screening assay needs to be automatable, 
time efficient and reliable. Following, the different development and optimization steps 
leading to a HT compatible estrogen-morphology (E-Morph) assay set-up are described. 
3.2.1. Optimization of staining method and computational analysis  
As a first step, seeding and treatment of cells was scaled up from a 6- or 12-well 
plate format to a 96-well plate format, and the imaging of cells was moved from manual 
imaging using a Zeiss LSM 880 AiryScan Confocal Microscope to automated imaging 
of predefined sections with the Opera Phenix HC Screening System.  
First, it was tested whether AJ reorganization upon Fulv treatment could still be 
robustly detected in this new set-up. MCF7/vBOS cells seeded into 96-well plates were 
treated for 48h and stained for E-Cad by immunofluorescence staining (Figure 19 a). 
Notably, the previously described AJ reorganization could again be observed upon Fulv 
treatment showing that the new plate format as well as the imaging modality did not 
have any influence on the detection of the effect. Next, the images were analyzed with 
the integrated image analysis software Harmony following the same principle as the 
CP/CPA pipeline described above (Section 3.1.1). The cells were again classified into 
regular and irregular AJ organization and the MI was calculated. 
Essential for a good test method is a sufficiently high dynamic range, which is 
represented by the signal separation between the positive and negative controls. Thus, 
the signal window (SW) and Z’ value (Z’) of Fulv treated cells and the solvent control 
were determined. Indicators for a good signal separation are a SW above 2 or a Z’ 
above 0.4 [108]. With scores of 6.99 and 0.48 respectively, both SW and Z’ indicated 
sufficient signal separation. Hence, scaling to a 96-well plate format, automation of the 
imaging, and image analysis pipeline was deemed successful.  
As immunofluorescence staining is time consuming and involves many sample 
preparation steps, alternative and more efficient cell staining methods were tested. 
MCF7/vBOS cells were again treated with 10 nM Fulv for 48 h and stained with the two 
live cell stains LysoTracker and CellTrace (Figure 19 b, c). In contrast to the E-Cad 




membrane but the cytoplasm to indicate cell morphology. More specifically, 
LysoTracker specifically stains, as the name already suggests, the lysosomes while 
CellTrace covalently binds to intracellular proteins per se and thus represents a more 
general staining method to visualize the cytoplasm. In accordance, the LysoTracker 
staining was generally more granular than CellTrace. Whereas the outlines of individual 
cells were difficult to discriminate in solvent control cells in both staining methods, the 
cells appeared to be clearly separated upon Fulv treatment. The irregular AJ 
organization detected by E-Cad staining correlated with an increased spacing between 
cells upon LysoTracker and CellTrace staining. Subsequently, the images were 
analyzed using the Harmony image analysis software. For the three different staining 
methods, cells could be successfully classified into regular and irregular AJ 
organization and the MI determined. Generally, the determined MI values were in a 
similar range as with low throughput set-up. Additionally, calculation of the SW and Z’ 
revealed a similar signal separation for LysoTracker staining and a better separation for 





Figure 19: CellTrace cytoplasmic staining is sufficient for differentiation between regular and 
irregular adherens junction organization. 
a-c) MCF7/vBOS cells were treated with 10 nM Fulv for 48 h and stained a) for E-Cad with 
immunofluorescent staining, b) with LysoTracker and c) CellTrace (scale bar= 25 µm). Image analysis 
and cell classification was done with the integrated image analysis software Harmony. The Morphology 
Index is defined as the fraction of cells showing regular adherens junction organization normalized to the 
solvent control. The line indicates the mean distribution with error bars indicating the standard deviation. 
One dot represents one well with analyzed 9 images. The results of three biological replicates are shown. 
Signal window (SW) and Z’ were calculated as described by Iversen et al [108]. The values represent the 










Next, the performance of the three different staining methods were further 
compared in two different dose response set-ups – phenotype formation and prevention. 
In the phenotype formation set-up, MCF7/vBOS cells were treated with different 
concentrations of Fulv for 48 h (Figure 20 a-c). In the phenotype prevention set-up, the 
cells were co-treated with 10 nM Fulv and different concentrations of E2 for 48 h 
(Figure 20 d-f). Subsequently, cells were stained with the three different staining 
methods and the images analyzed using the Harmony software (Figure 20).  
In the phenotype formation set-up, the MI values remained close to the solvent 
control at low Fulv concentrations in all three staining methods (Figure 20 a). They 
slowly started decreasing at 0.5 nM, before reaching a plateau at Fulv concentrations 
between 10 nM and 100 nM Fulv, thus showing a similar trend as can be seen in 
Figure 2 and Figure 4 shown above for the low-throughput CP image analysis set-up. 
No striking differences between the staining methods concerning MI values or the dose 
response curve were observed and the IC50 values were all in the same range. The MI 
of the immunofluorescence-stained cells reached its plateau slightly sooner, but also at a 
higher MI score of 0.5, while the MI of LysoTracker and CellTrace decreased to a value 
of around 0.25 indicating an increased sensitivity. Notably, staining with CellTrace 
resulted in the smallest within-plate and between-plate variance across technical and 
biological replicates.  
In the phenotype prevention set-up, at low concentrations of E2, the MI value 
across the different staining methods was around 0.5 and slowly increased before 
reaching 1.0 at 10 nM E2. These results are again in agreement with results shown in 
Figure 5. Similar to the phenotype formation set-up, all MI values of the different 
staining methods were in same range and showed comparable dose-response curves and 
EC50 values. Notably, CellTrace staining again showed the least variance of the three 
staining methods.  
Taken together, these results show that quantification of the AJ organization is 
also possible by visualizing the cytoplasm using the two live cell stains LysoTracker 
and CellTrace. As quantification of the CellTrace-stained cells showed the lowest 
variance and the best signal separation, all subsequent assay development steps for the 






Figure 20: The different staining methods show all similar dose-response curves. 
a-c) MCF7/vBOS cells treated with different concentrations of Fulvestrant (Fulv) for 48 h. 
d-f) MCF7/vBOS cells treated with 10 nM Fulv and different concentrations of 17β-estradiol (E2). 
a-f) Cells were stained for E-Cadherin for immunofluorescent staining, with LysoTracker and CellTrace. 
Image analysis and cell classification was done with the integrated image analysis software Harmony. 
The Morphology Index is defined as the fraction of cells showing regular adherens junction organization 
normalized to the solvent control. One dot represents one biological replicate consisting out of three 
different wells with nine images each. The dose response curves were fitted using the non-linear fit 
algorithm (three parameters, hill slope= 1) by GraphPad. The error bars indicate the standard deviation. 
 
As already mentioned, quantification of AJ reorganizations was conducted using 
the integrated commercial image analysis software Harmony, while previous 
experiments described in the first part of this thesis were analyzed using an analysis 
pipeline based on the free CP/CPA software. To show that quantification of AJ 
reorganization is independent of the software used, the images of the CellTrace staining 
were additionally exported and evaluated using a CP/CPA pipeline (Figure 21). The SW 
and Z’ values were nearly indistinguishable from the values obtained with the Harmony 
software while the minor  differences between the obtained IC50 or EC50 values were 
within the variance of the biological replicates. To conclude, it was also possible to 






Figure 21: Quantification of CellTrace stained cells can also be conducted with a CellProfiler/ 
CellProfiler Analyst analysis pipeline. 
a) MCF7/vBOS cells were treated with 10 nM Fulv for 48 h. The results of three biological replicates are 
shown. Signal window (SW) and Z’ were calculated as described by Iversen et al [108]. The values 
represent the mean value of the three biological replicates. b) MCF7/vBOS cells treated with different 
concentrations of Fulvestrant (Fulv) for 48 h. c) MCF7/vBOS cells treated with 10 nM Fulv and different 
concentrations of 17β-estradiol (E2). a-c) Cells were stained with CellTrace. Image analysis and cell 
classification was done with CellProfiler/CellProfiler Analyst. The Morphology Index is defined as the 
fraction of cells showing regular adherens junction organization normalized to the solvent control. One 
dot represents one biological replicate consisting out of three different wells with 9 images each. The 
dose response curves were fitted using the non-linear fit algorithm (three parameters, hill slope= 1) by 
GraphPad. 
 
3.2.2. Optimization of the measuring time point 
Next to being easy in handling, a test method should be as time efficient as 
possible. Additionally, shorter incubation times might also decrease unspecific toxicity 
of the test substance and, thus, might allow testing of higher concentrations. In the 
experiments described in the first part of this thesis (Section 3.1), 48 h were used as the 
standard incubation time. Here, it was now tested whether the incubation time could be 
further optimized.  
To get a first approximation of the timing of the morphological changes, MCF7 
cells stably expressing GFP-tagged E-Cad (MCF7/E-CadGFP) were used in a time 
course experiment. The cells were treated with 10 nM Fulv for 24 h and then imaged 
every 2 h using the HC microscope Opera Phenix. The images were analyzed using the 
Harmony software and the MI was determined (Figure 22 a). At 24 h, the MI of the 
treated cells was still at the level of the solvent control but decreased to a level of 
around 0.25 after 40 h of treatment. Although the two biological replicates slightly 
differed in the early kinetics of phenotype development, the MI of both replicates 
reached a plateau at a value of 0.25 indicating that full AJ reorganization can be 
generally expected after about 40 h.  
From these results, selected time points were analyzed in the MCF7/vBOS cell 




MCF/vBOS was taken into account by also including a period below 40 h. MC7vBos 
cells were treated with different concentrations of Fulv for five different incubation 
periods – 30 h, 40 h, 48 h, 72 h, and 144 h – and subsequently imaged and analyzed 
(Figure 22 b). For all five incubation periods, a Fulv concentration of 0.1 nM did not 
induce AJ reorganization. The MI started to decrease at 1 nM Fulv and reached a 
plateau at around 100 nM. The different incubation times mainly differed in the MI 
value that was reached at the highest Fulv concentration. The maximum signal 
separation (dynamic range) was obtained at the 30 h and 48 h time points, while the 
72 h time point had only a minor additional benefit. Thus, the 30 h and 48 h time points 
were further validated according to the requirements for a HC screening assay published 
by Iversen et al [108]. In three independent biological repeat experiments, each three 
96-well plates of MCF7/vBOS cells were treated with 10 nM Fulv (representing the 
“Min” signal range), the solvent control (representing the “Max” signal range) and a 
combination of 10 nM Fulv and 3 nM E2 (representing the “Mid” signal range) for 30 h 
and 48 h, then imaged and quantified. The results were analyzed with regard to the 
within-day and between-day signal distribution as well as signal-to-noise ratio 
(SW and Z’). The MI distribution of the different plates and replicates as well as the 
corresponding SW and Z’ is shown in Figure 22 c-d. While the within-day and between-
day signal distribution (variance) was sufficiently small for the 48 h time point, the 30 h 
time point did not pass this validation requirement for a HC screening assay. 
Additionally, whereas for the 48 h time point, all plates had a SW > 2 or a Z’ > 0.4, 
several plates of the 30 h time point fell short on this criterion. These results show that a 
30 h treatment period was not sufficient to reliably and stably induce AJ reorganization 






Figure 22: Treatment of the cells for 48 h is the ideal time point. 
a) MCF7/E-CadGFP cells were treated with 10 nM Fulvestrant (Fulv), stained for the nuclei with 
Hoechst 33342 and imaged at 37 °C every 2 h for 24 h, n= 2. b) MCF7/vBOS cells treated with 
different concentrations of Fulv for different time periods (30-144 h). Cells were stained with 
CellTrace, n= 1. c-d) MCF7/vBOS treated with 10 nM Fulv (gray) and solvent control (black) for 
c) 30 h or d) 48 h in three different plate layouts and in three independent runs following the 
validation protocol suggested by Iversen et al [108]. a-d) The Morphology Index is defined as the 
fraction of cells showing regular adherens junction organization normalized to the solvent control. 
Image analysis and cell classification was done with the integrated image analysis software 
Harmony. One dot represents one biological replicate consisting out of three different wells with 








3.2.3. Definition of a cytotoxicity read-out 
A key confounder of results in in vitro testing is unspecific cytotoxicity of the 
test substance. Thus, an endpoint addressing potential cytotoxicity is ideally included in 
the E-Morph Assay set-up to directly exclude results of those test substance 
concentrations or to define the maximal, relevant testing concentration. There are 
different assays or endpoints to demonstrate cytotoxicity available that differ in their 
sensitivity, specificity, and applicability for a given assay set-up. Here, the applicability 
of three different endpoints – CellTox Green intensity (addressing membrane integrity), 
number of cells (addressing proliferation or general cytotoxicity), and conversion of the 
CellTiter Blue reagent (addressing proliferation, metabolism) – was analyzed. An 
overview of these readouts is shown in Figure 23 a. CellTox Green is non-membrane 
permeable dye that upon intercalation into the DNA can be excited at a wavelength of 
485-510 nm. As it can only penetrate the cell and interact with the DNA when the cell 
membrane is disrupted, high CellTox Green intensity in the nuclei corresponds to 
cytotoxicity of the substance (Figure 23 b). This endpoint could easily be integrated into 
the assay set-up by adding the dye after staining with Hoechst 33342 and CellTrace, and 
measuring the mean CellTox Green intensity in the area of nuclei. The number of cells 
is an accepted marker for cytotoxicity and cell proliferation. Determination of this 
parameter was already part of the image analysis pipeline as described so far and did not 
require any adaptation of the assay set-up. The CellTiter Blue assay is a measure of the 
redox potential and metabolic capability of the cells as it depends on the conversion of 
the redox dye resazurin into the fluorescent resorufin. As the resulting amount of 
resorufin also directly depends on the incubation time and its fluorescence spectrum 
additionally would interfere with the other fluorescence signals, this cytotoxicity assay 
was not integrated into the imaging set-up but was performed after (see Section 7.2 for 
more detail). The three endpoints were evaluated by treating MCF7/vBOS cells with 
three cytotoxic substances – Triton X 100, 5-fluorouracil, and sodium azide – with 
known mechanisms of cytotoxicity (Figure 23 c-e). As expected, the CellTox Green 
intensity increased with increasing substance concentrations, while the number of cells, 
defined by the number of nuclei, declined. The CellTiter Blue readout decreased in a 
similar fashion for 5-fluorouracil and sodium azide, while remaining constant for 
Triton X 100. The most sensitive endpoint was the number of nuclei, generally showing 
an effect even before significant changes could be detected in CellTox Green or 




cytotoxicity thresholds were defined for CellTox Green (two-fold signal induction) and 
number of cells (15 % reduction of cell number) endpoints that are indicated in 
Figure 23 c-d by the dotted lines.  
Subsequently, it was tested whether Fulv treatment on its own affected any of 
the selected cytotoxicity endpoints. While no striking differences between Fulv 
treatment and the solvent control were observed for CellTox Green intensity or number 
of cells endpoints, the signal of the CellTiter Blue assay was consistently lower in Fulv-
treated cells than the solvent control. Estrogen signaling is known to influence 
proliferation and the metabolism of cells [85, 109]. As the cells were seeded to reach 
confluence before treatment, the inhibiting effect of Fulv on cell proliferation should be 
minimal. Therefore, the lower CellTiter Blue signal for Fulv was likely not due to 
cytotoxicity of the substance but a decrease in estrogen-dependent cell metabolism. In 
addition, the mean CellTiter Blue signal appeared to vary greatly between individual 
replicates something not observed for the other two endpoints.  
To conclude, although all three endpoints were able to indicate cytotoxicity, 
CellTiter Blue appeared to be the least predictive. The CellTiter Blue assay was not able 
to correctly identify the cytotoxicity of Triton X 100 and showed effects in Fulv treated 
cells. Furthermore, additional incubation and measurement steps would be needed. 
Therefore, only CellTox Green and number of cells were included as cytotoxicity 





Figure 23: Number of cells and CellTox Green are appropriate markers for cytotoxicity.  
a) Overview of the different cytotoxicity endpoints as well as substances that were tested. 
b) MCF7/vBOS cells treated with 0.005 % Triton X 100 for 48 h and stained with Hoechst and CellTox 
Green, scale bar= 50 µm. c)-e) The line indicates the mean value and the error bars the standard 
deviation. One dot represents one well consisting out of 9 images. f) MCF7/vBOS cells treated with 
different concentrations of Triton X 100 48 h. g) MCF7/vBOS cells treated with different concentrations 
of 5-Fluorouracil for 48 h. h) MCF7/vBOS cells treated with different concentrations of sodium azide for 
48 h. f)-h) Cells were first stained for CellTrace, Hoechst 33342 and CellTox Green, imaged and then 
incubated for 120 min with the CellTiter Blue reagent. The fluorescence signal of CellTiter Blue reagent 
was then measured separately. The dotted lines represent the cytotoxicity thresholds for CellTox 
Green (2, green) and number of cells (0.85, black). f) CellTox Green mean intensity value of cells treated 
with Fulvestrant (Fulv) and the solvent control stained with CellTox Green. g) Number of segmented 
cells in the wells treated with Fulv and the solvent control and stained with Hoechst 33342. h) CellTiter 
Blue signal intensity after 120 min incubation with cells treated with Fulv and the solvent control for 
48 h. c)-h) The values were normalized on the mean value of the solvent control. The experiment was 
conducted in biological replicates with 3 wells per treatment and 9 images per well. The error bars show 









3.2.4. Definition of a prediction model using a test set of six substances 
After optimization of the staining procedure and integration of the two cytotoxicity 
endpoints, the E-Morph Assay was then used for pilot testing of six reference chemicals 
with known estrogenic potential – two strong estrogenic substances 
(17α-Ethinylestradiol (EE), DES), two weak estrogenic substances (Gen, BPA) as well 
as two negative substances (Atrazine (Atra), Reserpine (Reserp)). MCF7/vBOS cells 
were treated with 10 nM Fulv and the six substances in twelve concentrations for 48 h. 
Following, the cells were stained with Hoechst 33342, CellTox Green and CellTrace, 
imaged and analyzed with the image analysis software Harmony (Figure 24 a-c; 
Figure 25 a-c). Apart from Atra, all substances crossed the predefined cytotoxicity 
thresholds for the number of cells and CellTox Green intensity endpoints 
(see Section 3.2.3) at the highest concentrations as indicated by the grey area. The 
number of cells often decreased already at slightly lower concentrations than an 
increase in CellTox Green intensity was observed. Under treatment of Atra, the number 
of cells rather increased than decreased and CellTox Green intensity remained constant 
(Figure 24 a-b), indicating that Atra is not toxic in the tested concentration range. At 
non-cytotoxic concentrations, the MI of the two strong estrogenic substances EE and 
DES reached the level of the solvent control already at low concentrations between 
10 nM and 100 nM, while a higher concentration of 1 µM of the weak estrogen Gen 
was needed. The MI of the BPA-treated cells increased with higher concentrations to a 
value between 0.75 and 0.8 but did not fully reach the level of the solvent control. The 
MI of Atra and Reserp increased at low concentrations but reached a plateau at a value 
of 0.7. 
To verify the results from the pilot testing and define an appropriate threshold of 
the MI readout that indicates estrogenicity, the six tested substances were further tested 
for their estrogenic potential by analyzing their gene expression profile (Figure 24 d; 
Figure 25 d). MCF7/vBOS cells were cotreated with 10 nM Fulv and the six substances 
at selected concentrations for 48 h, and the expression of the estrogen responsive genes 
PGR, EGR3, and PDZK1 was analyzed. For EE, DES, and Gen, the cotreatment 
completely prevented the Fulv-induced inhibition of the gene expression at 1 nM, 
10 nM, and 10 µM, respectively, while only a slight induction of gene expression was 
observed for BPA at 10 µM. No effect on the gene expression was detected for the two 
negative substances Atra and Reserp. Notably, comparing the MI values and the gene 




0.75 at concentration where a rescue of the gene expression was observed. Thus, the 
threshold for the classification of a test substance as estrogenic/positive was set to an 




Figure 24: Testing of three substances with different estrogenic potential. 
a-d) MCF7/vBOS cells treated with 10 nM Fulvestrant (Fulv) and different concentrations of 
17α-Ethinylestradiol (EE), Genistein (Gen), and Atrazine (Atra) for 48 h. a)-c) Cells stained for 
Hoechst 33342, CellTox Green, and CellTrace and analyzed with the image analysis software Harmony. 
The experiment was conducted in biological replicates with 3 wells per treatment and 9 images per well. 
The error bars show the standard deviation. The horizontal dotted lines represent the defined thresholds 
for number of cells (0.85), CellTox Green (2), and the Morphology Index (0.75). The grayed-out area 
indicates concentrations with cytotoxicity. a-b) values were normalized to 10 nM Fulv control. c) The 
Morphology Index is defined as the fraction of cells showing regular adherens junction organization 
normalized to the solvent control. d) Log2 mRNA fold change of PGR, EGR3, and PDZK1 of 







Figure 25: Testing of three substances with different estrogenic potential. 
a-d) MCF7/vBOS cells treated with 10 nM Fulvestrant (Fulv) and different concentrations of 
Diethylstilbestrol (DES), Bisphenol A (BPA), and Reserpine (Reserp) for 48 h. a)-d) Cells stained for 
Hoechst 33342, CellTox Green, and CellTrace and analyzed with the image analysis software Harmony. 
The experiment was conducted in biological replicates with 3 wells per treatment and 9 images per well. 
The error bars show the standard deviation. The horizontal dotted lines represent the defined thresholds 
for number of cells (0.85), CellTox Green (2), and the Morphology Index (0.75). The grayed-out area 
indicates concentrations with cytotoxicity. a-b) Values were normalized to 10 nM Fulv control. c) The 
Morphology Index is defined as the fraction of cells showing regular adherens junction organization 
normalized to the solvent control. d) Log2 mRNA fold change of PGR, EGR3, and PDZK1 of 










Based on the results shown in Sections 3.2.3 and 3.2.4, it was possible to define 
appropriate acceptance criteria to assess the results of the test method and to establish a 
prediction model to identify substances with estrogenic potential. A schematic overview 
is shown in Figure 26. For a valid run, a sufficient signal separation (SW > 2 or 
Z’ > 0.4) needs to be present in the controls (10 nM Fulv and solvent control). Next, 
cytotoxic concentrations of the test substance are excluded from further analysis. The 
prediction model describes the criteria for a final classification of a test substance as 
estrogenic/positive or negative. A substance is classified as estrogenic if in at least two 
out of three runs the MI crossed the threshold of 0.75 at least at one tested 




Figure 26: Schematic view of the acceptance criteria and the prediction model for the testing of 
















As weakly estrogenic substances were not able to show a full dose-response 
curve before being cytotoxic, it was not possible to calculate an EC50 value for this 
class. Therefore, to estimate the relative potency of all tested substances, the logarithmic 
concentration where the MI equals 0.75 was calculated (referred to as MI75). The 
calculated MI75 values of the four estrogenic substances showed the expected order of 
estrogenic potency, with EE being the strongest and BPA being the weakest estrogenic 
substance (Table 1). 
 
Table 1: Classification and MI75 of the six tested substances.  
MCF7/vBOS cells treated with 10 nM Fulvestrant and the listed six substances for 48 h. Cells were 
stained with Hoechst 33342, CellTox Green, and CellTrace and analyzed with the image analysis 
software Harmony. The experiment was conducted in three biological replicates with three wells per 
treatment and nine images per well. The MI75 is defined as the calculated logarithmic concentration 






Rep. 1 Rep. 2 Rep. 3 Mean 
17α-Ethinylestradiol 
(EE) 
Steroid POS -8.42 -8.86 -8.22 -8.50 
Diethylstilbestrol 
(DES) 
Stilbestrol POS -8.09 -7.68 -8.18 -7.98 
Genistein (Gen) Isoflavone POS -5.76 -6.84 -6.34 -6.31 
Bisphenol A (BPA) Phenol POS -6.38 -4.38 - -5.38 
Atrazine (Atra) Triazines NEG -4.36 - - - 
















3.2.5. Validation of the E-Morph Assay with eleven additional substances 
With a prediction model now in place, eleven additional substances were tested. 
The substances were selected for their known estrogenic potential and their diversity in 
structure (Table 2). Additionally, different bisphenols were included, that are discussed 
as alternatives for BPA. MCF7/vBOS cells were cotreated with 10 nM Fulv and the 
eleven substances at different concentrations for 48 h, stained, imaged and analyzed as 
described above. Upon applying the acceptance criteria and prediction model described 
in Section 3.2.4 and summarized in Figure 26, the substances were classified as 
estrogenic/positive and negative, and the MI75 was calculated. The results are listed in 
Table 2. As expected, E2 and E1 had the lowest MI75 value with -8.62 and -7.97, 
respectively, followed by Coumestrol (Coum) (MI75= -6.85) and Zea (MI75= -6.59). 
BPB and BPS had the highest MI75 values, while Progesterone and Ketoconazole were 
classified as negative. 
 
Table 2: Classification and MI75 of the eleven additionally tested substances.  
MCF7/vBOS cells treated with 10 nM Fulvestrant and the listed eleven substances for 48 h. Cells were 
stained with Hoechst 33342, CellTox Green, and CellTrace and analyzed with the image analysis 
software Harmony. The experiment was conducted in three biological replicates with three wells per 
treatment and nine images per well. The MI75 is defined as the calculated logarithmic concentration 






Rep. 1 Rep. 2 Rep. 3 Mean 
17β-Estradiol (E2) Steroid POS -8.36 -8.68 -8.82 -8.62 
Estrone (E1) Steroid POS -8.01 -7.99 -7.93 -7.97 
5α-Dihydro-
testosterone (DHT) 
Steroid POS -5.02 -5.64 -6.82 -5.82 
Zearalenone (Zea) Lactone POS -6.77 -6.51 -6.49 -6.59 
Bisphenol AF(BPAF) Phenol POS -6.37 -5.21 -5.27 -5.62 
Bisphenol B (BPB) Phenol POS -4.52 -4.33 -4.35 -4.40 
Bisphenol S (BPS) Phenol POS -4.51 -4.08 -4.48 -4.36 
Daidzein (Dai) Isoflavone POS -4.89 -5.52 -6.14 -5.52 
Coumestrol (Coum) Isoflavone POS -7.02 -6.87 -6.65 -6.85 
Progesterone (PG) Steroid NEG - - -5.81 - 










To better compare and visualize the data of the in total 17 tested substances, the 
MI75 values were normalized to the mean MI75 value of the known potent estrogen EE 
(Figure 27). Four different categories could be defined – strong (rel. MI75 > 0.9), 
medium (0.9 > rel. MI75 > 0.6), weak (0.6 > rel. MI75), and negative (rel. MI75= 0). 
The tested endogenous and pharmaceutical estrogens completely made up the category 
of the strong estrogens, while the phytoestrogens were all medium estrogenic. The 
endogenous androgen 5α-dihydrotestosterone, the mycotoxin Zea and Bisphenol AF 
(BPAF) were also in that category. The other three bisphenols (BPB, BPS, BPA) tested 
were categorized as weak estrogens. Progesterone, Ketoconazole, Atra and Reserp were 
classified as negative, which is indicated by a MI75 of zero.  
 
Figure 27: Relative MI75 values of the 17 tested substances. 
MCF7/vBOS cells treated with 10 nM Fulvestrant and the listed 17 substances for 48 h. Cells stained for 
Hoechst 33342, CellTox Green, and CellTrace and analyzed with the image analysis software Harmony. 
The experiment was conducted in three biological replicates with three wells per treatment and 
nine images per well. The relative MI75 is defined as the logarithmic threshold concentration where the 
Morphology Index met 0.75 relative to the mean MI75 of 17α-Ethinylestradiol. The black line indicates 
the median of the three repeats (dot). The colors indicate the “estrogenicity” of the substance 












3.2.6. The predictive capacity of the E-Morph Assay 
Two in vitro assay set-ups – receptor binding (OECD TG 493) and receptor 
transactivation (OECD TG 455) – were approved to be part of the OECD testing 
strategy for identification of substances with estrogenic potential (see 
Section 1.2.2) [77, 78]. Additionally, in the year 2015, the EPA as part of their ToxCast 
project published an ER model integrating the results of 18 in vitro assays into an ER 
agonist score [84]. To understand the predictive capacity of the E-Morph Assay, the 
relative MI75 values from the 17 tested substances were compared to the published 
reference data of the available test methods (Figure 28). For better comparison, the 
logarithmic EC, IC or PC values of the reference data were also normalized to the value 
of EE, respectively. Generally, the relative MI75 appeared to correlate very well with 
the published results. The four substances (Atra, Reserp, Ketoconazole and 
progesterone) identified as negative were also negative in the protein binding and 
transactivation assays. Atra, Reserp and Ketoconazole in the ToxCast model also had an 
ER agonist score of zero, while progesterone with an ER agonist score 0.05 was there 
categorized as very weakly estrogenic. The endogenous and pharmaceutical estrogens 
were again grouped together as the more potent estrogens though the exact order of 
estrogenicity differed between the assays. The classified weak and medium estrogenic 
substances were also less estrogenic in the published assays. Altogether, most of the 
tested substances localized on or very close to the dashed reference line indicating very 
similar relative estrogenicities when compared to the individual reference assays. 
Interestingly, in some cases e.g. 5α-dihydrotestosterone, the estrogenic potency 
appeared to also vary greatly between assays addressing the same endpoint.  
In conclusion, it could be shown, that the E-Morph Assay yielded comparable 
results as compared to internationally accepted individual assays for the identification of 
estrogenic substances and even had a similar predictive capacity as compared to the 






Figure 28: Correlation of the relative MI75 values of the tested substances to the published data of 
other assays. 
a-c) MCF7/vBOS cells were treated with 10 nM Fulvestrant and the listed 17 substances for 48 h. Cells 
stained for Hoechst 33342, CellTox Green, and CellTrace and analyzed with the image analysis software 
Harmony. The experiment was conducted in three biological replicates with three wells per treatment 
and nine images per well. The relative MI75 is defined as the logarithmic threshold concentration where 
the Morphology Index (MI) met 0.75 relative to the mean MI75 of 17α-Ethinylestradiol (EE). The 
median values are shown. The contour line is indicated by the dotted line. a) The relative MI75 values 
set against the results of the two estrogen receptor protein binding assays – Freyberger-Wilson Assay 
and CERI Assay – normalized to EE [77]. b) The relative MI75 values set against the results of the two 
transactivation assays (TA) – stably transfected TA Assay  and VM7-Luc-ER TA assay – normalized to 








The important role of estrogen signaling during breast cancer development and 
progression has long been recognized [5, 21, 23]. Even though the exact mechanism is 
still under debate, several factors seem to contribute. Next to their effects on cell 
proliferation, estrogens have been discussed to influence E-Cad expression levels and 
cytoskeleton organization [33-35, 110]. Although several test methods for the 
identification and characterization of estrogenic environmental substances have been 
developed in recent years, most of them only cover the initial steps of estrogen signaling 
activation (e.g. binding and transcription activation) and only a single assay with a 
functional endpoint exists (E-SCREEN assay). This work introduces a novel 
HT-compatible test method, the E-Morph Assay, for the identification and 
characterization of estrogenic substances with AJ reorganization as a functional 
endpoint.  
4.1. Adherens junction reorganization is estrogen receptor α mediated 
Cells used in a test method for estrogenic substances need to be estrogen 
responsive and ideally well-characterized. Having retained ERα and E-Cad expression, 
the MCF7 cell line is an established model for luminal A breast cancer. The 
MCF7/vBOS cell line used in this work, which is a sub-clone of the parental 
MCF7/BOS cell line [88], is characterized by high ERα expression levels and strong 
estrogen responsiveness. The strong estrogen responsiveness could be verified in 
MCF7/vBOS cells by analyzing the gene expression of estrogen responsive genes after 
treatment with the estrogen E2, or the two antiestrogens Fulv and 4-OHT (Section 3.1, 
Figure 1). Although E2 treatment did not cause any changes on gene expression levels, 
treatment with either of the two antiestrogens significantly reduced the gene expression 
levels of the tested estrogen responsive genes. According to their characteristics as 
SERD and SERM respectively, the inhibition of estrogen responsive gene expression 
was stronger upon Fulv treatment than compared to 4-OHT. The lack of responsiveness 
towards E2 treatment was likely due to full saturation of the estrogen signaling capacity 
through residual E2 in the medium and sequestration of involved transcription factors. 
An induction of estrogen responsive gene expression beyond the level of the solvent 
control could only be achieved when the cells were cotreated with E2 and Fulv 
(Section 3.1.2, Figure 5). This effect may be explained by a reduced sequestration of the 




treatment considerably depleted the available pool of ERα through its action as a SERD. 
Due the use of FCS with low hormone levels and reduction of FCS supplement under 
experimental conditions, the residual E2 levels in the cultivation medium (3.4-4.1 pM) 
are expected to be in the range of serum levels of postmenopausal women [111]. 
Additionally, the necessary Fulv concentration for the effective inhibition of estrogen 
responsive gene expression was similar to the steady-state plasma levels of patients 
undergoing Fulv-based endocrine therapy [112].   
This work is mainly based on the observation that modulation of ERα signaling 
induces a striking AJ reorganization in MCF7/vBOS cells [87]. To ensure the 
applicability of AJ reorganization as an endpoint for the specific identification of 
estrogenic substances, the role of the different estrogen receptors ERα and GPER1 was 
studied in more detail (Section 3.1.2). Taken together, ERα could be verified as a key 
component involved in the modulation of AJ organization, while a significant role of 
GPER1 appears to be rather unlikely. Already the timing of AJ reorganization 
occurrence indicates a more prominent role of ERα as compared to GPER1. AJ 
reorganization took at least 28-30 h to develop (Section 3.2.2, Figure 22). While ERα 
directly mediates changes in gene expression and long-term effects, GPER1 is rather 
responsible for rapid non-genomic signal transduction [11]. Generally, treatment with 
different antiestrogens (ERα antagonists) induced AJ reorganization in a dose-
dependent manner corresponding to their inhibitory effects on estrogen responsive gene 
expression (Section 3.1.1). Additionally, the known potency was also reflected in timing 
of the phenotype. Induction of AJ reorganization was much faster under Fulv treatment 
than under Tam. High concentrations of Fulv as well as other ERα antagonists are 
known to also activate GPER1 signaling [11, 16], however treatment with the GPER1 
specific activator G1 did not have any effects on AJ reorganization (Section 3.1.2, 
Figure 6). Additionally, although E2 and Fulv both are thought to activate GPER1 
signaling, titration of the estrogen E2 against a fixed concentration of the antiestrogen 
Fulv prevented AJ reorganization at concentrations in line with published binding 
affinities to the ERα (Section 3.1.2, Figure 5) [90]. Similarly, E1, which is reported to 
have no binding affinity towards GPER1 [11], could prevent AJ reorganization in the 
pilot screen (Section 3.2.5, Table 2). Specific inhibition of ERα signaling by siRNA-
mediated ERα KD resulted in AJ reorganization, while GPER1 KD neither induced nor 
prevented AJ reorganization (Section 3.1.2, Figure 5, Figure 8). It needs to be 




only verify KD efficiency of ERα protein, while GPER1 KD efficiency could only be 
controlled at the mRNA level as no appropriate GPER1 antibody could be identified. 
Thus, it cannot be fully excluded that, due to low protein turnover and high protein 
stability, GPER1 protein levels may have remained sufficiently high to retain their 
functionality. The role of GPER1 was further investigated using the small molecule 
inhibitors G15 and G36 (Section 3.1.2, Figure 6, Figure 7). G15 could prevent Fulv-
mediated but not ERα KD-mediated AJ reorganization, while G36 did not have any 
effect. Although G15 and G36 show similar antagonistic effects towards GPER1, it was 
reported that G15 in contrast to G36 can also bind to ERα and act as partial agonist of 
ERα-mediated transcription [94]. As G15 did only prevent Fulv-mediated but not ERα 
KD-mediated AJ reorganization, competitive displacement of Fulv through G15 at the 
ERα level appeared to be a plausible explanation. However, titration of G15 against a 
fixed concentration of Fulv did not significantly rescue Fulv-induced inhibition of 
estrogen responsive gene expression levels (Section 3.1.2, Figure 6). Additionally, 
increasing concentrations of Fulv against a fixed concentration of G15 could only 
partially rescue AJ reorganization (Section 3.1.2, Figure 7). Although competitive 
displacement of Fulv through G15 at the ERα level might in part explain the G15-
mediated prevention of Fulv-induced AJ reorganization, other yet unknown 
mechanisms of Fulv and G15 action are likely involved and require further 
investigation. Cotreatment studies of G1, G15 and Fulv might help to further elucidate 
the action of G15.  
Altogether, the data supports a causal relationship of ERα signaling inhibition 
and AJ reorganization. Regardless of the inconclusive results concerning G15 action, a 
significant involvement of GPER1 seems unlikely and AJ reorganization is primarily 
mediated through the ERα signaling pathway.  
4.2. Adherens junction reorganization is a functionally relevant 
endpoint 
In contrast to other endpoints such as receptor binding (OECD TG 493) or 
receptor transactivation (OECD TG 455), AJ reorganization is a more functionally 
relevant endpoint with regard to cancer development and progression.  
Tumor progression, invasion and metastasis are in part dependent on the 
adhesiveness of the cancer cells [32]. Cell adhesion is primarily mediated by 




expression levels are thought to be a hallmark in cancer progression [32]. However, 
recent research shows that expression levels alone are not necessarily indicative of 
prognosis and adhesion [31, 113]. While interaction between two individual E-Cad 
proteins of adjacent cells is rather weak, it is strengthened by lateral E-Cad 
clustering [27, 28]. The E-Cad ectodomains engage into trans (with neighboring cells) 
as well as cis (with E-Cad proteins of the same cell) interactions and both interactions 
are required for effective adhesion. Additionally, the actin cytoskeleton and lipid 
environment contribute the organization of E-Cad proteins into tightly packed 
nanoclusters as well as microclusters [28]. AJ reorganization seems to correlate with 
increased cell-cell adhesion through E-Cad microclusters. Upon AJ reorganization, 
E-Cad distribution converged from a continuous/regular to a discontinuous/irregular 
distribution. Additionally, while no change on CDH1 mRNA levels were observed, AJ 
reorganization correlated with higher E-Cad protein levels likely through decreased 
protein turnover (Section 3.1.1, Figure 3). It was shown that the pool of E-Cad 
accessible to Trypsin cleavage was reduced upon AJ reorganization (Section 3.1.3, 
Figure 9). Trypsin is a serine protease endogenously found in the digestive system but is 
also standardly used to dissociate cells in cell culture. Whereas the amount of full-
length E-Cad decreased upon Trypsin digestion in the solvent control, its levels 
remained unchanged in Fulv-treated cells displaying AJ reorganization. Accordingly, 
the additional low molecular weight bands emerging from the Trypsin digestion were 
also less pronounced in Fulv-treated cells even though total protein levels were 
elevated. As engagement of E-Cad in nano- or microclusters decreases the accessibility 
to proteases like Trypsin, it can be concluded, that next to AJ reorganization and 
increased E-Cad protein levels also the amount of E-Cad engaged in clusters is elevated. 
Similarly, Fulv-treated cells with induced AJ reorganization showed an increased 
resilience against calcium deprivation (Section 3.1.3, Figure 9). Incubation with the 
calcium chelating agent EGTA causes rounding of cells as E-Cad trans interactions are 
highly calcium dependent. Following, the amount intercellular E-Cad homodimers are 
reduced upon EGTA addition. The cell-cell contacts are lost, and the cells display a 
rounded morphology. As all non-covalent bonds exist in equilibrium and E-Cad at the 
membrane is subject to protein turnover, the time needed for full cell-cell contact 
detachment and rounding is depending on E-Cad clustering, protein turnover, and total 
amount of E-Cad intercellular dimers. Cell rounding occurred much faster in solvent 




cells already exhibited rounded cell morphology after 40 min of incubation in the 
solvent control, nearly all Fulv-treated cells had still intact cell contacts. Even at the end 
of the measured time period of 120 min only about 20 % of the Fulv-treated cells 
showed rounded cell morphology whereas the fraction of rounded cells was twice as 
high in the solvent control. Thus, in line with the other results, also the quantitative 
calcium resilience assay indicates increased E-Cad clustering, decreased protein 
turnover and higher total amount of E-Cad intercellular dimers upon AJ reorganization.  
Overall, the data conclusively links E-Cad microcluster formation by AJ 
reorganization with increased levels of bound E-Cad at the membrane – both of which 
are indicative of increased cell adhesion [28, 95]. Highlighting the functional relevance 
of AJ reorganization as endpoint for the identification of estrogenic substances, these 
findings are also important in the context of breast cancer therapy. Inhibition of 
estrogen signaling through ERα antagonists or aromatase inhibitors is an essential part 
in therapy of ERα-positive breast cancer [21]. Published results addressing the influence 
of ERα signaling on CDH1 expression have been rather contradictory [33-35] and 
E-Cad levels alone have been shown to not be fully predictive of cancer 
progression [31, 113]. Increased adhesion through ERα-mediated AJ reorganization 
might represent another possible beneficial effect of endocrine therapy.   
4.3. Signaling pathways involved in adherens junction reorganization 
In addition to strengthening the functional relevance of AJ reorganization as 
endpoint for estrogenic substances, an understanding of the involved signaling pathways 
is important for the identification of potential false positive predictions from a screening 
assay. Figure 29 summarizes the key findings from this work about the relevant singling 







Figure 29: Working model for estrogen receptor α induced adherens junction reorganization.  
Activation of estrogen receptor α (ERα) signaling upon 17β-estradiol (E2) binding induces Amphiregulin 
(AREG) expression.  At the membrane, AREG is processed and secreted. As an autocrine or paracrine 
growth factor, AREG activates the epidermal growth factor receptor (EGFR) signaling pathway. Through 
src family of kinases (SFK), RhoA or other regulators of the cytoskeleton regular adherens junction (AJ) 
organization is formed. Disruption of this signaling pathway causes irregular AJ organization/AJ 
reorganization. Disruption can happen through ERα signaling inhibition (antiestrogens (Fulvestrant 
(Fulv), 4-hydroxytamoxifen (4-OHT)); siRNA ERα knock down (KD)), AREG KD, inhibition of the 
EGFR (Gefitinib) or the modulation of cytoskeleton (PP1/PP2 or Rhosin). Red dot indicates 
phosphorylation. 
 
AREG is part of the EGF family of growth factors and known to activate EGFR 
signaling in a juxta- and paracrine manner. In contrast to other EGFR ligands, 
expression of AREG is strongly estrogen-dependent and regulated by ERα activity. 
Ciarloni et al found that E2 treatment of ovariectomized mice specifically induced Areg 
expression but not of the other EGF ligands, while no Areg induction was observed in 
ERα KD mice [97]. Additionally, EREs were identified around the AREG promotor 
region in vitro and in vivo [1, 114]. Cell culture experiments with another MCF7 sub-
clone showed a modulation of AREG expression depending on ERα signaling 
activity [98]. Additionally, it was reported that the xenoestrogen BPAF induced cell 
proliferation through ERα-mediated AREG expression and EGFR activation 
highlighting the relevance of AREG in EDC research [115]. In MCF7/vBOS cells, 
AREG was found to be one of the first genes to be significantly downregulated upon 
Fulv treatment with a two-fold inhibition after 4 h and a hundred-fold inhibition of 
expression levels after 48 h (Section 3.1.3, Figure 10). Similarly, the ERα KD resulted 
in a reduction of AREG mRNA and protein levels. In addition, it could be shown that 




equimolar concentration of E2, and its expression levels could even been induced at 
higher E2 concentrations similar to other estrogen responsive genes (Section 4.1).  
ERα-dependent AREG expression and EGFR signaling are crucial for the correct 
development and organization of the mammary duct as demonstrated in KD studies in 
mice. KD of ERα, AREG or EGFR impaired pubertal outgrowth of the ductal 
epithelium and ductal malformation upon ERα KD could be prevented by exogenous 
AREG administration [1, 97]. While AREG and EGFR are essential in the development 
of the mammary duct, both are also implicated in breast cancer development and 
progression [37, 44, 96]. Overexpression of AREG and EGFR in breast cancer is 
correlated with larger tumor size and cancer progression [37, 44]. AREG is discussed to 
be responsible for EGFR-mediated cell proliferation and invasion [44]. In MCF7/vBOS 
cells, the ERα-AREG-EGFR signaling axis was also found to be involved in the 
development of AJ reorganization (Section 3.1.3, Figure 10, Figure 11). Low AREG 
expression levels coincided with AJ reorganization and prevention of AREG 
downregulation also prevented the formation of AJ reorganization. Moreover, siRNA-
mediated KD of either ERα or AREG induced AJ reorganization, while hAREG-GFP 
overexpression was able to restore endogenous AREG expression levels and prevent 
Fulv-mediated AJ reorganization. It was previously reported that next to ERα signaling, 
AREG expression can also be induced through an EGFR-dependent positive feedback 
loop [43, 44]. A rescue of endogenous AREG expression through hAREG-GFP 
overexpression thus indicates functional activity of the ectopically expressed AREG 
protein and an activation of the EGFR signaling pathway. In line with these findings, 
the small molecule EGFR inhibitors Gefitinib, PD153035, and BIBX1382 induced AJ 
reorganization as well (Section 3.1.3, Figure 11).  
Notably, treatment with the EGFR inhibitors also caused a downregulation of 
ERα target gene expression levels including AREG (Section 3.1.3, Figure 11). As all 
three structurally different inhibitors had similar inhibitory effects on estrogen 
responsive gene expression, these changes are rather unlikely to be caused by off-target 
effects on the ERα. This bidirectional crosstalk between the ERα and the EGFR 
signaling pathway has also been reported in several publications [9, 11, 13]. While ERα 
mediates the expression of growth factors like AREG, EGFR signaling can influence 
ERα phosphorylation and thus activity [116]. Britton et al showed a direct relationship 
between AREG-dependent EGFR/MAPK signaling pathway activation and ERα 




induces Ser 118 phosphorylation, addition of the EGFR inhibitor Gefitinib results in 
reduced phosphorylation [114]. Similarly, Migliaccio et al reported a modulation of 
ERα phosphorylation at several sites by EGFR signaling and SFK activation [101, 116]. 
Upon phosphorylation, ERα associates with SFK and forms a complex, which induces 
ligand-independent estrogen responsive gene expression. Interestingly, this complex 
also in turn influences EGFR phosphorylation and activity [116]. Notably, while all the 
three small molecule EGFR inhibitors caused a general downregulation of estrogen 
responsive gene expression in MCF7/vBOS cells, a modulation of AREG levels (KD or 
overexpression), and thereby EGFR activity, itself did not influence ERα activity 
(Section 3.1.3, Figure 10) suggesting the involvement of additional growth factors.  
Notably, an about two-fold upregulation of EGFR total protein levels could also 
be consistently observed upon AJ reorganization in MCF7/vBOS cells across all 
treatment conditions (Fulv/4-OHT treatment or ERα/AREG KD), which was however 
not reflected at the EGFR mRNA level (Section 3.1.3, Figure 11). The mechanism 
underlying this observation needs to be addressed by further studies. As AJ 
reorganization was a result of AREG depletion and EGFR signaling inhibition, the 
increased EGFR protein levels might be the result of a post-transcriptional 
compensatory mechanism. Additionally, E-Cad and EGFR are able to directly interact 
with each other at the cell membrane [26]. E-Cad expression and EGFR signaling 
activity are inversely correlated and EGFR signaling inhibition induces E-Cad 
upregulation and adhesion [117]. In MCF7/vBOS cells, AJ reorganization coincides 
with increased E-Cad clustering and protein levels. Thus, increased EGFR protein levels 
could also be caused by reduced turn over and membrane fluidity due to entrapment in 
E-Cad clusters. As interaction of E-Cad negatively influences EGFR signalling activity, 
E-Cad clustering might further strengthen EGFR inhibition and AJ reorganization. 
While an involvement of AREG in AJ reorganization could be clearly shown, further 
research is needed to fully elucidate the underlying mechanism and the role of the 
EGFR in the formation of AJ reorganization.  
To conclude, while endpoints such as ERα transactivation or binding only 
address specific parts of the entire ERα signaling pathway in a rather artificial 
environment, the ERα-dependent AJ reorganization addressed by the E-Morph Assay 
represents an endpoint with a clear functional relevance. Moreover, as ERα-mediated 
AJ reorganization directly correlated with increased E-Cad clustering and involved the 




potential clinical relevance with regard to cancer progression and invasion, which 
remains to be investigated in more detail.   
4.4. Adherens junction reorganization as an endpoint in a high-
throughput compatible test method for estrogenic substances – 
the E-Morph Assay 
Based on the collected data showing that AJ reorganization is mainly ERα 
dependent in MCF7/vBOS cells, AJ reorganization was used as an endpoint for 
developing a HT-compatible test method, referred to as the E-Morph Assay. In this 
assay, AJ reorganization can be used for both the identification of ERα agonists as well 
as antagonists depending on the set-up. ERα antagonists are identified directly by their 
capacity to induce AJ reorganization and ERα agonists are indirectly identified by their 
capacity to prevent Fulv-induced AJ reorganization. As most of the EAS act rather as 
ERα agonists than antagonists, it was decided to first establish the agonist set-up that is 
described in this thesis (Figure 30). In the E-Morph Assay, seeded cells are cotreated 
with a fixed concentration of Fulv and increasing concentrations of the test substance. 
Following, the cells are stained and then imaged using an automated high-content 
microscope. Finally, a machine learning-based image analysis pipeline allows the 
analysis of AJ organizations and thereby a characterization of the estrogenicity of a test 
substance.  
 
Figure 30: Schematic view of the E-Morph Assay.  
MCF7/vBOS cells were seeded into a 96-well plate. The following day, 10 nM Fulv and different 
concentrations of the test substance were applied to the cells. Medium was exchanged the next day. After 
48 h of incubation, the cells were stained with CellTrace, Hoechst 33342, and CellTox Green. Image 
acquisition was done with Opera Phenix High Content microscope. Image analysis was conducted with a 
machine learning based image analysis pipeline build within the integrated image analysis software 
Harmony. 
 
The development process included several adaptation and optimization steps to 
achieve high efficiency and robustness of the assay. The cell staining was switched 
from E-Cad immunofluorescent stain to an indirect cytoplasmic staining (Section 3.2.1, 




AJ organization was not possible, cytoplasmic staining was found to be much faster and 
additionally had a better signal separation. During image analysis using the integrated 
Harmony software, cell segmentation is a multistep process including identification of 
nuclei as seeding points for the following detection of cell outlines based on a 
cytoplasmic staining. Direct membrane identification based on E-Cad staining is not a 
built-in option and more prone to mistakes during segmentation resulting in error prone 
classifications and decreased signal separation. The time point analysis confirmed 48 h 
to be the ideal incubation period as an incubation period shorter than 48 h was shown to 
be unfavorable with regard to signal separation due to incomplete AJ reorganization, 
while an incubation period beyond 48 h did not significantly improve classification 
(Section 3.2.2, Figure 22). Still, it is possible to test more than 12 substances a week in 
this set-up with still manual treatment and staining. Further optimization and 
automation of these steps will increase the throughput.  
A key confounder of results in in vitro testing is cytotoxicity of the test 
substance. Often times, cytotoxicity is measured separately or only the cell count is 
included in an assay set-up. In the E-Morph Assay, addition of the CellTox Green dye 
during staining and minor adaptations of the image analysis pipeline enabled the easy 
integration of CellTox Green mean intensity and number of cells as two independent 
cytotoxicity endpoints (Section 3.2.3, Figure 23). Testing of three different substances 
with known cytotoxic properties underlined the performance of both endpoints in 
predicting cytotoxicity. Further optimization of the staining and imaging procedure 
might even increase the predicative capacity of CellTox Green. CellTox Green stains all 
dead or dying cells with impaired membrane integrity. As the staining procedure 
includes several washing steps, large amounts of dead cells are washed off. While it 
increased the sensitivity of the cell count as endpoint, it limited to the detection of dying 
but still attached cells. Addition of CellTox Green to and imaging of the cells prior to 
the general cell staining process might increase sensitivity, but would mean further 
steps. The CellTiter Blue assay is often used as a cytotoxicity marker [118]. Although 
being generally indicative for cytotoxicity, it was shown to not be an ideal endpoint in 
the E-Morph Assay as it was sensitive to ERα-dependent changes in the metabolic state 
of cells and also required additional sample preparation procedures. 
To conclude, it was possible to develop a test method for the identification of 
estrogenic substances. Optimized staining procedures and image analysis enable the 




endpoints number of cells and membrane integrity. Future work will go towards the 
integration of the E-Morph Assay in a full automatic HT system. 
4.5. Characterization of the limitations and applicability of the 
E-Morph Assay  
The biologic and mechanistic relevance of AJ reorganization as an endpoint for 
a test method to identify and characterize estrogenic substances has already been 
described in detail in the previous paragraphs (Section 4.1 to 4.3). In addition, the 
applicability domain of a test method describing its applicability and limitations to 
certain groups of chemicals or reactivity mechanisms needs to be clearly characterized. 
Certain limitations arise from the general in vitro assay set-up. Generally, for 
appropriate cell treatment, the substance needs to be soluble in the used medium. As 
only one cell line is used in an artificial 2D set-up, representation of toxicokinetics is 
very limited. In addition, barrier functions are also not reflected in this assay. However, 
the amount of Fulv used is physiologically relevant and in the future, physiologically 
based pharmacokinetic modelling models might allow the definition of bioavailable 
concentrations that might at least partially compensate for limitations of in vitro assays 
in respect to absorption, distribution, metabolism, and excretion. Similarly, breast cells 
do not have the same metabolic capacity as for example liver cells [119]. Substances 
that need specific metabolic activation might not be active in the E-Morph Assay. 
Likewise, substances which are normally rapidly metabolized to inactive compounds 
might appear as highly active. 
As illustrated in the working model (Section 4.3, Figure 29), multiple signaling 
pathways are involved in AJ reorganization including ERα and AREG-EGFR, but also 
SFK and RhoA. The role of AREG and the EGFR signaling pathway for AJ 
reorganization has been discussed in detail in the previous Section 4.3. From these data 
one can conclude that test substances inducing AREG expression or activating EGFR in 
an ERα-independent manner may prevent Fulv-induced AJ reorganization and would 
consequently be detected as false positives in the E-Morph Assay. Similarly, EGFR 
inhibitors could possibly strengthen AJ reorganization independent of their estrogen 
action and be detected as false negatives. Analysis of estrogen responsive gene 
expression might help support the final decision. With regard to the applicability 
domain of the E-Morph Assay, the role of SFK as a downstream pathway of EGFR 




Fyn could be excluded, as neither the c-src-specific small molecule inhibitor kb-src4 nor 
Fyn KD influenced AJ organization, the small molecule SFK inhibitors PP1 and PP2 
were able to efficiently induce AJ reorganization. PP1 and PP2 are standardly used as 
specific SFK inhibitors. Still, it is important to consider, that even though PP1 and PP2 
are known to inhibit the activity of several SFK, publications by Bain et al show that 
they also act off-target on other kinases such as C-terminal src kinase (CSK) or cyclin 
G-associated kinase (GAK) [120, 121]. As already mentioned previously, SFK are 
known to be involved in the bidirectional crosstalk of ERα signaling and EGFR activity 
and influence ERα transcriptional activity [116]. While upon Fyn KD the expression 
level of AREG remained unchanged, PP1 and PP2 caused a downregulation of AREG 
expression. Interestingly, the expression levels of the other estrogen responsive genes 
remained unchanged (TFF1) or were even induced (PGR) indicating indirect 
modulation of the ERα potentially through changing its phosphorylation status.  
Additionally, cotreatment with E2 or G15 could also partially prevent PP2-induced AJ 
reorganization in a similar fashion as observed for Fulv-induced AJ reorganization, 
altogether indicating a crosstalk with ERα signaling.  
Although this data points towards the involvement of SFKs or other PP1/2-
inhibited kinases, the underlying mechanism by which PP1 and PP2 induce AJ 
reorganization remains to be clarified. To further elucidate a potential crosstalk with 
ERα, a thorough analysis of its phosphorylation status would be required. 
Independently, test substances influencing SFK may not be correctly identified 
concerning their estrogenicity.  
Potential influences of the Rho GTPases Rac1, Cdc42, and RhoA/C on AJ 
reorganization have been investigated as well. Rho GTPases are major players in the 
regulation of actin cytoskeleton organization as well as AJ formation and 
maintenance [27]. In addition, Rho GTPase activity itself can be influenced by EGFR 
and SFK signaling [41]. A significant role in AJ reorganization of rac1 and cdc42 could 
be excluded as neither inhibition of Rac1 nor cdc42 through small molecule inhibitors 
had any effect. The role of RhoA however is still less clear. RhoA activation either 
through a RhoA activator or overexpression of constitutively active RhoA prevented AJ 
reorganization induced by Fulv or PP2. In contrast, inhibition of RhoA using the 
RhoGEF12/LARG-specific RhoA inhibitor Y16 [107] or overexpression of 
constitutively inactive RhoA had no effect. However, Rhosin, a direct small molecule 




expression of estrogen responsive genes, AREG as well as RHOA and RHOC. While 
modulation of ERα activity through the differential expression levels RHOA and RHOC 
has been discussed before [122], KD of RhoA or RhoC did not cause any obvious 
changes in AREG expression or AJ reorganization. Thus, an off-target effect of Rhosin 
on ERα cannot be excluded. Generally, although RHOC is induced upon Fulv 
treatment, no connection between AJ reorganization and RhoA or RhoC expression 
levels could be found at this point, as also overexpression of RhoA or RhoC did not 
influence AJ reorganization in any way.  
Although further research is needed to fully characterize the role of RhoA in AJ 
reorganization, the data so far suggests a more permissive rather than instructive role of 
RhoA in AJ reorganization. RhoA is a major hub in cytoskeleton regulation and the 
prevention of AJ reorganization might just be the result of general changes in 
cytoskeleton organization. Nevertheless, these data indicate that test substances 
modulating the architecture of the actin cytoskeleton, e.g. by activating RhoA, may be 
detected as false positives in the E-Morph Assay, therefore limiting its applicability 
domain.   
4.6. Characterization of the predictive capacity of the E-Morph Assay 
In addition to the applicability domain, the predictive capacity of a test method 
is a key determinant describing its performance as compared to e.g. reference test 
methods that are accepted by regulatory agencies. A test set of six substances of known 
estrogenic potential was used to define a prediction model for the E-Morph Assay. After 
passing the initial quality control step permitting only plates with sufficient signal 
separation for further analysis, substances with an MI value above 0.75 at any non-toxic 
concentration in two out of three runs were defined as estrogenic/positive. The 
prediction model was then used to assess the estrogenic potential of an additional set of 
eleven reference substances that were also in part used in the validation of receptor 
binding (OECD TG 493) or receptor transactivation (OECD TG 455) assays, both 
internationally accepted. The relative MI75 (interpolated concentration at which the 
0.75 threshold was crossed) of all 17 tested substances correlated well with relative 
logarithmic EC50 values from both assays (receptor binding (OECD TG 493) or 
receptor transactivation (OECD TG 455)) and further confirmed the ERα-dependency 
of the selected endpoint. Even Gen, known to also inhibit EGFR [75] thus a possible 
false-negative, was able to prevent AJ reorganization at reasonable concentrations. The 
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relative MI75 values correlated slightly better with the relative logarithmic IC50 of the 
Freyberger-Wilson Assay than compared to the CERI Assay with the relative value of 
5α-dihydrotestosterone being the main difference. While the CERI assay uses the ERα 
binding domain produced in Escherichia coli, the Freyberger-Wilson Assay utilizes the 
full-length ERα protein made by insect cells [77]. In addition to protein length, also the 
expression system might influence the binding affinity as Escherichia coli and insect 
cells are known to have different capacities in protein folding and posttranslational 
modifications. Interestingly, the relative MI75 values correlated better with the stably 
transfected TA assay using ERα-HeLa cells than compared to the MCF7 based 
VM7-Luc-ER TA assay [78]. MCF7 cells are known for their clonal heterogeneity and 
their responsiveness to estrogens can vary greatly [88, 123]. The relative MI75 values 
also correlate well with EPA ToxCast ER agonist score. The ToxCast score is, in 
contrast to the other values, not a relative value derived from an effect concentration but 
a cumulative score derived from the results of 18 different assays. The good correlation 
highlights the good predictive capacity of the test method. 
5. Conclusion and Outlook 
 This thesis describes the development of a novel test in vitro method – the 
E-Morph Assay – that allows the identification and characterization of estrogenic 
substances. In contrast to most existing in vitro assays, the E-Morph Assay has a 
functional endpoint, i.e. AJ reorganization, encompassing complex cellular 
mechanisms. Similar to cell proliferation as the endpoint in the E-SCREEN assay, AJ 
reorganization is also clinically relevant with regard to cancer progression. AJ 
reorganization was shown to be mediated by the ERα/AREG/EGFR signaling pathways 
and correlated with the clustering of E-Cad at the cell membrane and increased cell 
adhesion.  
According to the A concept, multiple assays can be combined to cover the MIE 
and KEs leading towards an adverse effect [80]. While in vitro assays for the first two 
KE of ERα signaling activation (receptor binding and transcription activation [80]) 
exist, there is a need for new in vitro assays with functional endpoints which cover more 
complex KE. The E-SCREEN with proliferation as endpoint was so far the only 
functional assay. On its own, the E-Morph Assay cannot replace in vivo assays. 
However, it can contribute towards covering more complex KE in an ERα signaling 
AOP. Initial testing of 17 substances showed a good predictive capacity for 
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identification and characterization of estrogenic substances. Additionally, because of the 
direct relevance of AJ reorganization in the context of breast cancer, the E-Morph assay 
might be useful in the development of new drugs against breast cancer.  
Further investigation is needed towards elucidating the underlying molecular 
mechanism downstream of ERα/EGFR and the functional relevance of AJ 
reorganization. Immuno-histological analysis of breast cancer section of antiestrogen-
treated patients should be analyzed to underline the clinical relevance of this finding and 
the new potential beneficial effects of endocrine therapy. Testing of more substances 
with known and unknown estrogenic potential will be required to further define the 
predictive capacity and applicability domain of the E-Morph Assay. Internal and 
external validation studies to define the transferability and reliability of the E-Morph 
Assay would a prerequisite for the regulatory acceptance at international level, e.g. 






Table 3: List of equipment and machines used. 
Equipment Manufacturer 
Apotome.2 Zeiss 
Axio Observer.Z1 Zeiss 
CKX41 inverted microscope Olympus life science 
Countess II FL Automated Cell Counter Invitrogen 
EcoVac vacuum pump schuett-biotec 
Fusion Solo 6S Vilber 
GENios Tecan 
Mastercycler nexus gradient Eppendorf 
Mini-Protean 3 cell Bio-Rad 
Nanodrop 2000 spectrophotometer ThermoFisher Scientific 
Opera Phenix High Content screening system Perkin Elmer 
QuantStudio 7 Flex Applied Biosystems 
THERMOstar BMG Labtech 
Thermostat 5320 Eppendorf 
Trans-Blot SD Semi-Dry transfer cell Bio-Rad 
Zeiss LSM 880 AiryScan Confocal Microscope Zeiss 
ZOE Fluorescent Cell Imager Bio-Rad 
 
6.2. Cell culture  
Cell culture reagents 
Table 4: List of all the used cell culture reagents. 
Name Manufacturer Order number 
BioFreeze Biochrom/Merk F 2270 
CellTiter-Blue Cell Viability Assay Promega G8080 
DMEM 1 g/l Glucose phenol red free  Gibco 11880-028 
DMEM 1 g/l Glucose with Glutamine Biochrom/Merk FG0415 
Dulbecco’s Phosphate-Buffered Saline (PBS) PAN biotech P04-36500 
EGTA Roth 3054.1 
Fetal bovine serum Biochrom/Merk S0613 
FuGENE HD Transfection Reagent Promega E2311 
Glutamax (100x) Gibco 35050-38 
HiPerFect Transfection Reagent Qiagen 301705 
Opti-MEM Gibco 51985034 
Penicillin/Streptomycin Biochrom/Merk A2212 





Table 5: Cell culture media compositions 
Name Composition 
Complete medium 
DMEM 1 g/l Glucose with Glutamine 
10 % FBS 
1 % Penicillin/Streptomycin 
Minimal medium 
DMEM 1 g/l Glucose phenol red free 
5 % FBS 
1 % Penicillin/Streptomycin 
1 % Glutamax 
 
Cell lines 
For this thesis, the MCF7/vBOS derived from the original MCF7 cell line [88] 
specifically selected for their estrogen responsiveness and MCF7/E-CadGFP cell 
line [124] were used.  
6.3. Staining reagents 
Cell labeling reagents 
Table 6: List of all the cell labeling reagents used. 
Name Company Order number 
4‘,6-Diamidibo-2-phenylindole (DAPI) Sigma D9542 
CellTox Green Dye, 1,000x Promega G8731 
CellTrace  Far Red Cell Proliferation 
Kit 
Life Technologies C34564 
Hoechst 33342, Trihydrochloride, 
Trihydrate – 10 mg/mL Solution 
ThermoFisher Scientific H3570 
LysoTracker Deep Red  Life Technologies L12492 
 
Antibodies 
Table 7: List of the primary antibodies used. 
Name Manufacturer Order number 
Monoclonal Mouse Anti-E-Cadherin (G1) Santa Cruz sc-8426 
Monoclonal Mouse Anti-EGFR (A10) Santa Cruz sc-373746 
Monoclonal Mouse Anti-ERα (F10) Santa Cruz sc-8002 




BD 610 182 
Polyclonal Rabbit Anti-Amphiregulin Proteintech 16036-1-AP 
Polyclonal Rabbit Anti-E-Cadherin (H-108) Santa Cruz sc-7870 





Table 8: List of the secondary antibodies used. 
Name Manufacturer Order number 
Donkey anti-Mouse IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 488 
ThermoFisher Scientific A-21202 
Donkey anti-Mouse IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 555 
ThermoFisher Scientific A-31570  
Donkey anti-Mouse IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 647 
ThermoFisher Scientific A-31571 
Donkey anti-Rabbit IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 488 
ThermoFisher Scientific A-21206  
Donkey anti-Rabbit IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 555 
ThermoFisher Scientific A-31572 
Donkey anti-Rabbit IgG (H+L) Highly 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 647 
ThermoFisher Scientific A-31573 
Goat-anti-mouse- IgG-Horse-radish 
peroxidase 
Santa Cruz sc-2031 
Goat-anti-rabbit- IgG-Horse-radish 
peroxidase 
Santa Cruz sc-2004 
 
6.4. DNA and RNA constructs 
Plasmid 
Table 9: List of the plasmids used in this thesis 
Protein Vector-Backbone Supplier Cat. No 
pcDNA3-EGFP-RhoA-Q63L pcDNA 3-EGFP Addgene 12968 
pcDNA3-EGFP-RhoA-T19N pcDNA 3-EGFP Addgene 12967 
pcDNA3-EGFP-RhoA-WT pcDNA3-EGFP Addgene 12965 
pCMV6-AC-GFP-hAREG-GFP pCMV6-AC-GFP OriGene RG203150 









Table 10: List of the different siRNAs used in this thesis. All siRNAs were purchased by Qiagen as 






SI03049683; SI00299936; SI00299852; 
SI00299845 
ESR1 GS2099 
SI02781401; SI03114979; SI03065615; 
SI00002527 
FYN GS2534 
SI02659545; SI02654729; SI00605451; 
SI03095218 
GPER1 GS2852 
SI02776907; SI02654267; SI02654211; 
SI04434213 
RHOA GS387 
SI02776907; SI02654267; SI02654211; 
SI04434213 
RHOC GS389 







Table 11: List of primers for the quantitative polymerase chain reaction including their sequence 
and melting temperature TM. All primers were purchase by Eurofins. 
Gene  Sequence (5‘→3‘) TM 
YWHAZ 
forw ACT TTT GGT ACA TTG TGG CTT CAA 58.3 
rev CCG CCA GGA CAA ACC AGT AT 58.8 
CDH1 
forw AGG AGC CAG ACA CAT TTA TGG AA 58.9 
rev GCT GTG TAC GTG CTG TTC TTC AC 62.4 
PGR 
forw TCAACTACCTGAGGCCGGAT 58.5 
rev GCTCCCACAGGTAAGGACAC 56.3 
GPER1 
forw AGCGGACAAAGGATCACTCAG 58.3 
rev GGTGGGTCTTCCTCAGAAGG 57.7 
ESR1 
forw CCACCAACCAGTGCACCATT 60.7 
rev GGTCTTTTCGTATCCCACCTTTC 58.6 
EGFR 
forw GGCAGGAGTCATGGGAGAA 58.8 
rev GCGATGGACGGGATCTTAG 58.8 
AREG 
forw TGGATTGGACCTCAATGACA 56.7 
rev TAGCCAGGTATTTGTGGTTCG 65.4 
TFF1 
forw CATCGACGTCCCTCCAGAAGAG 62.1 
rev CTCTGGGACTAATCACCGTGCTG 61.7 




Gene   Sequence (5‘→3‘) TM 
EGR3 
forw GGTGACCATGAGCAGTTTGC 58.4 
rev ACCGATGTCCATTACATTCTCTGT 57.5 
PDZK1 
forw CTCCAGCTCCTACTCCCACT 55.2 
rev ACCGCCCTTCTGTACCTCTT 56.7 
RHOC 
forw AGCGGAAGCCCCACCAT 57.6 
rev CAGTGTCCGGGTAGGAGAGA 61.4 
RHOA 
forw AGCCAAGATGAAGCAGGAGC 58.6 
rev TTCCCACGTCTAGCTTGCAG 58.1 
 
6.5. Kits 
Table 12: List of the different kits used. 
Name Manufacturer Order number 
DNase Qiagen 79254 
High Capacity cDNA reverse transcription kit Applied Biosystems 4368814 




RNeasy Mini kit Qiagen 74106 
 
 
6.6. General material 
Table 13: List of chemicals with known or suspected endocrine effects. 
Name CAS Number Function Supplier 
Order 
number 
(Z)-4-Hydroxytamoxifen 68047-06-3 ERα Antagonist Tocris 3412 
17α-Ethinylestradiol 57-63-6 ERα Agonist Sigma E4876 
17β-Estradiol 50-28-2 ERα Agonist Sigma E8875 
5α-Dihydrotestosterone 521-18-6 Androgen Sigma A8380 
Atrazine 1912-24-9 Herbicide Sigma 90935 
Bisphenol A 80-05-7 Phenol Sigma 239658 
Bisphenol AF 1478-61-1 Phenol Sigma 90477 
Bisphenol B 77-40-7 Phenol Sigma 50877 
Bisphenol S 80-09-1 Phenol Sigma 43034 
Coumestrol 479-13-0 Isoflavone Sigma 27885 
Daidzein 486-66-8 Isoflavone Sigma D7802 
Diethylstilbestrol 56-53-1 ERα Agonist Sigma D4628 
Estrone 53-16-7 ERα Agonist Sigma E9750 
Fulvestrant 129453-61-8 ERα Antagonist Sigma I4409 
Fulvestrant 129453-61-8 ERα Antagonist Tocris 1047 
G1 881639-98-1  GPER1 Agonist Tocris 3577 
G15 1161002-05-6  GPER1 Antagonist Tocris 3678 
G36 1392487-51-2 GPER1 Antagonist Tocris 4759 
Genistein 446-72-0 Isoflavone Sigma G6649 




Name CAS Number Function Supplier 
Order 
number 
Progesterone 57-83-0 Hormone Sigma P0130 
Reserpine 50-55-5 Drug Sigma R0875 
Zearalenone 17924-92-4 Mycotoxin Sigma Z2125 
ZK164015 177583-70-9 ERα Antagonist Tocris 2183 
 
Table 14: List of inhibitors or activators of specific cellular pathways. 





1216920-18-1 EGFR inhibitor Tocris 2416 
Gefitinib/Iressa 184475-35-2 EGFR inhibitor Tocris 3000 
kb-src4 1380088-03-8 c-Src inhibitor Tocris 4660 
PD153035 183322-45-4 EGFR inhibitor Tocris 1037 
PP1 172889-26-8 SFK inhibitor Tocris 1397 
PP2 172889-27-9 SFK inhibitor Tocris 1407 
PP3 5334-30-5 EGFR inhibitor Tocris 2794 
Rho Activator II (CN03) - RhoA activator Cytoskeleton CN03-A 
Rhosin 1281870-42-5 RhoA inhibitor Tocris 5003 
Y16 429653-73-6 RhoA inhibitor Sigma SML0873 
 
Table 15: List of any additional material used. 
Name Manufacturer Order number 
30 % Acrylamide:Bisacrylamide  37.5:1 Bio-Rad 161-0158 
37 % Formaldehyde neoLab Migge 443.010.000 
4x Laemmli Puffer Bio-Rad 1610747 
5-Fluorouracil Sigma F6627 
Acetic acid 100 % Roth 6755.1 
Ammonium persulfate (APS) Roth 9592.3 
Bovine Serum Albumin (BSA) Sigma A4503 
Bromophenol blue Roth A512.1 
cOmplete Protease Inhibitor Cocktail Sigma  4693124001 
Dulbecco’s phosphate buffered 
saline (PBS) 
Sigma D5652 
Ethylenediaminetetraacetic acid (EDTA) Roth X986.1 
Glycine Sigma G8898 
Hydrogen chloride  Roth 4625.1 
Igepal CA630 Sigma I8896 
Methanol Merk 1.060.092.511 
Non Fat dry milk Roth T145.3 
PageRuler Plus prestained Protein  
ladder 
ThermoFisher Scientific  26619 
PhosSTOP Phosphatase Inhibitor 
Cocktail 




Name Manufacturer Order number 
Pierce SuperSignal West Femto  ThermoFisher Scientific 34095 
Pierce Western Blotting Substrate  ThermoFisher Scientific 32109 
PlusOne Coomassie Tablets, PhastGel 
Blue R-350 
GE Healthcare life 
science 
17-0518-01 
Ponceau S Roth 5938.1 
Power UP SYBR Green PCR Master 
Mix 
ThermoFisher Scientific 15310939 
Sodium azide Sigma S8302 
Sodium chloride Roth HNOO.3 
Sodium deoxycholate Roth 3484.1 
Sodium dodecyl sulfate (SDS) Bio-Rad 161-0301 
Tetramethylenediamine (TEMED) SERVA 35930 
Tris Roth 5429.2 
Triton X-100 Sigma T8787 
Tween-20 Roth 9127.1 
VectaShield VectorLabs H-1000 
β-Mercaptoethanol Sigma M7154 
 
6.7. Buffers and solutions 




Standard Lysis buffer 
Tris 20 mM 
NaCl 138 mM 
Glycerol 5 % (w/v) 
EDTA 4 mM 
Triton X-100 1 % (v/v) 
Boehringer Lysis buffer 
Tris/HCl pH 7.4 50 mM 
NaCl 150 mM 
Na-deoxycholate 0.1 % (w/v) 
SDS 0.1 % (w/v) 
Igepal CA630 1 % (v/v) 
EDTA, pH 8.0 5 mM 
EGTA 5 mM 
10x polyacrylamide gel 
electrophoresis (PAGE) buffer  
pH 8.3 
Tris 625 mM 
Glycine 4802.5 mM 
1x SDS Running buffer 
1000 ml 
10x PAGE buffer 100 ml 
10 % SDS 10 ml 
add H2O  
1x Transfer buffer 
250 ml 
10x PAGE buffer 25 ml 
Methanol 50 ml 







10 % polyacrylamide 
separation gel  
15 ml 
Acrylamide Mix (30 %) 5 ml 
1.5 M Tris/HCl pH 8.8 3.8 ml 
10 % SDS 150 µl 
H2O 5.9 ml 
10 % APS 150 µl 
TEMED 6 µl 
5 % polyacrylamide stacking gel  
5 ml 
Acrylamide Mix (30 %) 830 µl 
0.5 M Tris/HCl pH 8.8 0.63 ml 
10 % SDS 50 µl 
H2O 3.4 ml 
0.5 % Bromophenol blue 20 µl 
10 % APS 50 µl 
TEMED 5 µl 
10x Tris-buffered Saline (TBS) 
Tris 0.2 M 
NaCl 1.5 M 
TBS-T 1,000 ml 
10x TBS 100 ml 
Tween 20 1 ml 
add H2O  
0.1 % Ponceau S in 5 % Acetic 
acid 100 ml 
Ponceau S 0.1 g 
100 % Acetic acid 5 ml 
add H2O  
Coomassie Stock solution 
1 tablet/80 ml H2O  
add 120 ml Methanol  
Coomassie working solution 
100 ml 
Stock solution 50 ml 
Methanol 25 ml 
add H2O  
 
Distaining solution 100 ml 
100 % Acetic acid 10 ml 
Ethanol 50 ml 
add H2O 





7.1. Cell culture 
Maintenance 
The MCF7/vBOS as well as the MCF7/E-CadGFP cells were kept in full 
medium (see Table 5) and splitted into a new flask every three to four days in a dilution 
ratio between one to five and one to ten. After eight to ten passages, the cells were 
discarded, and a new batch of cells was thawed. The cell stock was kept frozen in 
BioFreeze in liquid nitrogen. 
Seeding and treatment 
If not noted differently, the cells were seeded in minimal medium in a 
concentration to reach confluence the next day. Treatment with the test substance or a 
combination of substances was started the following day after the cells had settled. 
Medium was changed daily. After a treatment period of two to three days, the cells were 
prepared according to the analysis method (see Sections 7.2 to 7.4).  
Quantitative calcium switch resilience assay 
The cells were seeded in a 96-well glass bottom view plate (Perkin 
Elmer 6005430) and exposed to 10 nM Fulv or the solvent control as described. After 
48 h, the cells were stained with CellTrace and Hoechst 33342 as defined in Section 7.2, 
no CellTox Green was added. After washing, minimal medium containing 8 mM EGTA 
was added to the cells. The cells were imaged as a time course experiment (images 
every 10 minutes for two hours) with the Opera Phenix HC microscope. Finally, the 
images were analyzed with the integrated Harmony software as described in 
Section 7.5. 
Effect kinetic with MCF7/E-CadGFP cells 
The effect kinetic experiment was conducted in a similar fashion as the 
quantitative calcium switch resilience assay. The MCF7-E-CadGFP cells were seeded in 
a 96-well glass bottom view plate (Perkin Elmer 6005430) and exposed to 10 nM Fulv 
and the solvent control as described. After 24 h, the cells were stained with 
Hoechst 33342 as defined in Section 7.2 and put into the Opera Phenix HC microscope 
at 37°C for imaging. Images were taken every 2 h for 24 h. At last, the images were 




Trypsin Resistance Assay 
For the Trypsin Resistance Assay, MCF7/vBOS cells were seeded into a 6-well 
plate and treated with 10 nM Fulv as described. After two days of treatment, the cells 
were washed with PBS and 300 µl Trypsin/EDTA solution was added. The cells were 
incubated for 4 min at 37 °C. Following, the supernatant was removed, and the proteins 
were extracted as described in Section 7.4. 
Transfection of siRNA and plasmids 
Depending on the analysis method, the cells were either seeded into a 12-well 
plate for RNA extraction (Section 7.3) or immunohistochemistry (Section 7.2) or into a 
6-well plate for protein extraction (Section 7.4). Transfection was either directly after 
seeding or the following day. If the transfection was done the following day, the cells 
were seeded to reach a 70-80% confluence on the day of transfection.  
siRNA transfection was done with the HiPerFect Transfection Reagent of 
Qiagen. For a 12-well plate, 10 nM siRNA and 9 µl of HiPerFect Transfection Reagent 
were used. For a 6-well plate, the reagent volumes were tripled, respectively. 
Plasmid transfection was done with the transfection reagent FuGene by 
Promega. Reagent and plasmid were used in a ratio of 3:1 – 3µl of reagent for 1 µg 
plasmid. 
The RNA or the plasmid was mixed with Opti-MEM and the transfection 
reagent was added. After 5-10 min incubation period, the mixture was added dropwise 
to the cells. The medium was exchanged the following day. 
 
7.2. Cell imaging methods 
Immunohistochemistry  
For immunohistochemistry, the cells were seeded in 12-well plates and 
transfected and/ or treated with substances as described in Section 7.1. At the day of 
sample preparation, the cells were rinsed with PBS two times and fixed for 15 min with 
3.7 % formaldehyde in PBS. Permeabilization was done for 30 min with a 0.2 % 
solution of Triton X 100 in PBS. Following, the cells were blocked for an hour with 5 % 
FBS. Incubation of the primary antibodies was done for either 90 min at room 
temperature or overnight at 4° C. DAPI and conjugated Phalloidin were added to the 
solution of the secondary antibodies. If not noted differently, all antibodies were diluted 




washed with PBS three times for 5 mins. Finally, the cells were mounted on a slide 
using 3 µl of VectaShield. Imaging was done either with Axio Observer.Z1 including 
the Apotome.2 module, the Zeiss LSM 880 AiryScan Confocal Microscope or the 
Opera Phenix HC system. Images at the Zeiss LSM 880 AiryScan Confocal Microscope 
were collected by Sebastian Dunst. 
CellTrace, Hoechst 33342 and CellTox for the test method 
The cells were seeded in a 96 glass bottom view plate (Perkin Elmer 6005430) 
a concentration of 80,000 cells/well/200µl and treated for 48 hours as described in 
Section 7.1. For staining, the medium was removed and PBS containing 1:1,000 diluted 
CellTrace and 1:500 diluted 10 mg/ml Hoechst 33342 was added. The cells were 
incubated for 20 mins at 37° C. Following, the cells were rinsed three times with 
minimal medium. For substance testing, minimal medium containing 1:10,000 diluted 
CellTox Green were added. The cells were then imaged at the Opera Phenix HC system.  
CellTiter Blue Cell Viability assay 
For cytotoxicity endpoint comparison, the toxic effect of the substances was 
additionally analyzed with CellTiter Blue Cell Viability assay. After imaging of the 
plate, the medium containing CellTox Green was removed and 200 µl fresh reduced 
medium containing 1:10 diluted CellTiter Blue reagent was added. The cells were 
incubated for 2 h at 37 °C. Subsequently, 100 µl of the supernatant were transferred into 
black 96-well microtiter plate and the fluorescence was measured at 560 (excitation)/ 
590 (emission) using a microplate reader. 
7.3. RNA biologic methods 
RNA extraction 
The cells were seeded and treated in 12-well plate as described in Section 7.1. 
The RNA extraction was conducted with the RNeasy kit by Qiagen following the 
manufactures instructions. In short, the cells were rinsed with PBS two times before 
350 µl RLT buffer were added. The solution was transferred into a 1.5 ml tube and 
mixed with an equal amount of 70 % ethanol before being relocated on the column. 
Between the two washing steps with RW1 buffer, the column was treated with a DNase 
digestion. The column was washed two times with RLT buffer before the RNA was 





Reverse transcription polymerase chain reaction (RT-PCR) 
The RT-PCR was standardly conducted right after the RNA extraction with the 
RT-PCR kit by Applied Biosystems following the manufactures instructions. 
Depending on the RNA yield, 0.5 µg or 1 µg RNA were used. The RT-PCR samples 
were diluted in a ratio 1:10 or 1:20 for the following quantitative real time polymerase 
chain reaction (qPCR). 
Quantitative real time polymerase chain reaction (qPCR) 
Subsequent to the RNA extraction and RT-PCR, the samples were analyzed with 
qPCR. For one qPCR reaction, 1 µl of 1:10 or 1:20 diluted cDNA sample was mixed 
with 5 µl of SYBR Green PCR master mix. Additionally, 0.25 µl of forward and reverse 
primer (10 µM stock solutions) were diluted in 5.5 µl RNase free water. Both mixtures 
were added together to a final volume of 11 µl. The PCR run method was conducted as 
described in Table 17. 
The results of the qPCR were analyzed via the ΔΔ CT methods. The CT value is 
the PCR cycle value, where the fluorescent signal of the dye passes a defined threshold 
in the linear area of the curve. Following, the CT value of the gene of interest is 
normalized to the housekeeper gene, in this case YWHAZ [125], by subtraction 
(ΔCT value). Subsequently, sample ΔCT value is subtracted of the control sample 




Table 17: PCR run method for qPCR analysis including melt curve analysis. 
Stage Duration Temperature [°C] 
Holding stage 
2 min 50 
10 min 90 
Cycling stage (40 cycles) 
15 s 95 
1 min 60 
Melt curve stage 
15 s 95 
1 min  60 (continuous to 95) 
30 s 95 






7.4. Protein biologic methods 
Protein extraction 
The cells were seeded in a 6-well plate and treated for 48 h as described in 
Section 7.1. Following, the cells were put on ice and rinsed two times with PBS. The 
PBS was removed and 150 µl of lysis buffer (standard or Boehringer) was added. The 
cells were scraped off and collected in a precooled 1.5 ml tube. The solution was placed 
on ice and incubated for 25-30 mins. Following, the cell debris was spun down for 
10 min at full speed. The supernatant was transferred to a new tube for further analysis. 
The pellet was discarded. 
Bicinchoninic acid assay 
For protein determination, the bicinchoninic acid (BCA) assay was employed. It 
builds on the principle that copper ions (2+) interact with the protein backbone in a 
basic solution and are reduced. The reduced ions complex with BCA and cause a 
protein concentration dependent color shift.  
In this study, the Pierce BCA protein assay kit was used following the manufacturer’s 
instructions. In short, 25 µl of 1:5 diluted protein samples were mixed with 200 µl BCA 
reagent (solution A and solution B in a ratio 50:1) and incubated for 30 min at 37 °C. 
Following, the optical density was measured at a wavelength of 590 nm. For total 
protein concentration determination, a standard series of defined BSA concentrations 
(0 µg/ml, 25 µg/ml, 125 µg/ml, 250 µg/ml, 500 µg/ml, 750 µg/ml, 1,000 µg/ml, 
1,500 µg/ml, 2,000 µg/ml) was included in every run. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Before Western blotting, the proteins were separated via SDS-PAGE. In 
preparation, 4x Laemmli sample loading buffer containing β-mercaptoethanol was 
added to the lysed protein samples and they were heated to 95 °C for 3 min. If not noted 
differently, 25 µg of protein was loaded on the gel. The SDS-gel consisted of a 5 % 
stacking gel and 10 % separation gel. The electrophoresis was run for 30 min on a 
constant voltage of 80 V and 60 min at 120 V. 
Western Blot and protein detection 
After protein separation via SDS-PAGE, the proteins were transferred on a 
membrane following the Western blot method. The two blotting techniques tank-blot 
and semi-dry were used. The principle is the same for both. The gel is placed on the 




electric field was applied in a way that caused the negatively charged proteins to 
transfer on to the membrane. For tank blot, only one filter paper was needed as the 
whole sandwich of gel, membrane and filter paper is placed vertically in a tank filled 
with blotting buffer and ice packs for further cooling. In semi-dry Western blotting, 
three pieces of filter paper on each side were used. There, the sandwich was placed 
horizontally between two plate electrodes. The tank blot was run for 120 min at constant 
400 mA, while the semi-dry blot was run at a constant voltage of 25 V for 90 mins.  
To check for a successful transfer, the membrane was rinsed with TBS and then 
stained for 1 min with 0.1 % Ponceau. The membrane was washed with TBS until the 
background was sufficiently removed. The Ponceau stain was recorded and then 
removed by subsequent washing with TBS. Following, the membrane was blocked with 
5 % milk powder in TBS-T for 30-60 min. Afterwards, 1:1,000 or 1:2,000 dilution of 
the primary antibody in blocking solution was added to the membrane and incubated at 
4 °C over night. The next day, the membrane was washed three times for 5 min with 
TBS-T and the blocking solution containing a horse radish peroxidase coupled 
secondary antibody in dilution of 1:2,000 was added. The membrane was incubated at 
room temperature for 2-5 h. The incubation period was followed by another washing 
step (3x5 min with TBS-T) and protein detection using the SuperSignal West Femto 
Chemiluminescent kit. Luminol Enhancer solution was mixed in equal volumes with the 
peroxide solution and spread on the membrane. After an incubation period of 5 min, the 
luminescence caused by the peroxidase can be detected using a gel documentation 
system. To saturate the peroxidase bound through the antibody to the membrane, the 
membrane was incubated 0.1 % sodium azide for 20 min.  
Coomassie staining of the membrane 
After complete immunodetection, a whole protein stain was done with 
Coomassie blue. The membrane was incubated with the Coomassie staining solution for 
1 min. Next, the membrane was destained to reduce the background by incubating it in 
the destaining solution overnight. When the membrane was sufficiently destained, it 






7.5.1. Analysis of Western blot data 
The Western blot image analysis was done using the software ImageJ [126]. The 
signal intensity was visualized in form of a histogram. The background was subtracted 
and the area under the curve was quantified. The resulting intensity values were then 
normalized on the Coomassie total protein stain and the corresponding control sample. 
7.5.2. Quantitative image analysis for adherens junction reorganization 
Quantitative image analysis was performed using a pipeline that built either on 
the integrated Harmony software or on a combination of CellProfiler and CellProfiler 
Analyst (CP/CPA analysis) [91, 92]. If not noted differently, all images collected at the 
Opera Phenix HC system were analyzed as maximum projection of a stack at least 
10 planes with the Harmony software and all images collected at Zeiss LSM 880 
AiryScan Confocal Microscope as a single image with a CP/CPA analysis pipeline.  
All image analysis pipelines can be divided into the same principle three steps – 
segmentation, extraction of cellular parameters, and a parameter-based classification of 
cells into two classes – regular AJ organization and irregular AJ reorganization.  
Image analysis Opera Phenix High Content data  
The segmentation of the nucleus and cytoplasm in the Harmony based pipeline 
were done with the Find Nuclei module (Method C) and Find Cytoplasm module 
(Method A), respectively. Following, cells at the edges were excluded (Select 
Population module). Cellular parameters were extracted using the STAR method 
(threshold compactness and profile) integrated into the Calculate Morphology 
Properties module. The parameter-based classification of the cells was done with the 
Linear Classifier method of the Select Population module. Supervised training was done 
on a subset of cells, followed by parameter-based automatic classification of all cells 
within the entire image dataset.  
For the MCF7/E-CadGFP time course experiment, each replicate was analyzed 
separately. Cytoplasm segmentation was done on the grounds of the stably transfected 
E-Cad-GFP signal. For the supervised training, 50 cells were selected for each of the 
two classes. For the comparison of the different cell staining methods, 60 cells with 
regular AJ organization and 60 with irregular AJ organization were selected from each 




test method, 40 cells per group per plate were used (a total of 360 cells per class). For 
the substance testing, additional 50 cells per class were added to the validation set. 
Lastly, CellTox Green was quantified in the nucleus region using the Calculate Intensity 
module. CellTox Green positive cells were determined with the Filter by Property 
method of the Select population module. The thresholds were set manually to the value 
of negative control with three times its standard deviation for each experiment. 
For comparison of the two image analysis software, a CP/CPA analysis pipeline 
was also build for images collected with Opera Phenix HC system. Two consecutive CP 
pipelines are needed. The first pipeline groups the exported raw images per well, field, 
and channel and conducts a maximum projection. Following, the projected images are 
loaded into the second image analysis pipeline. There, the nuclei were identified as the 
primary objects (nuclei) from the Hoechst 33342 channel by global thresholding using 
Otsu’s method. Starting from the nuclei, the cells (secondary objects) were defined with 
Watershed-Gradient method following the signal distribution of the CellTrace channel. 
Lastly, morphological parameters of the cells were measured with MeasureTexture 
module and the MeasureGranularity and written into a database file.  
The database file was imported into the Classifier module of the CPA software 
for supervised training with a subset of cells, and subsequent parameter-based automatic 
classification of all cells within the entire image dataset. Supervised training was 
conducted based on the cell morphology of the CellTrace channel with two classes – 
regular AJ organization and irregular AJ reorganization – with 60 cells sorted in each 
class respectively. The cytotoxicity endpoint CellTox Green was not included in the 
CP/CPA analysis. 
Image analysis of immunofluorescent images 
Quantitative image analysis of the immunofluorescent images stained for E-Cad 
was performed with a similarly build CP/CPA analysis pipeline. In the segmentation 
process, primary objects (nuclei) were also identified from DAPI staining by global 
thresholding using Otsu’s method. Additionally, the size of the nuclei was measured 
and nuclei with an area smaller than 1,000 px were filtered out. The correct 
segmentation of the nuclei was checked and if need be edited manually. Next, the 
secondary objects (cell) were defined using the Watershed-Gradient method with the 
primary objects serving as seeding points. Following, secondary objects that were 
touching the border or too large (> 8,000 px) (clumped nuclei) were excluded. The cell 




module MeasureTexture was used to extract cellular parameters of the cell membrane 
area and the data was stored in a database file.  
The database file was again imported into the Classifier module of the CPA software for 
supervised training. Supervised training based on cell membrane features (E-Cad 
channel) was conducted with two classes representing regular AJ and irregular 
AJ (50 cells per class). 
Quantitative image analysis of calcium switch resilience assay 
The principle image analysis for the quantitative calcium switch resilience assay 
was as described for the Harmony Software before. The cells were segmented into 
nucleus and cell. Following, morphologic parameters were calculated for the cell. In 
addition to the STAR method profile, the parameters for radial and axial cell symmetry 
were also included. Again, supervised training was done on a subset of cells followed 
by parameter-based automatic classification of all cells within the entire image dataset. 
The cells were classified into two classes – “rounded” and “not-rounded” cells.  
120 cells per class were used, respectively. Not-rounded cells were selected from each 
treatment at the first time point, rounded cells after 120 min treatment. Each replicate 
was analyzed independently. 
Statistical Analysis 
Generally, calculations were done either with Microsoft Excel or GraphPad 
Prism 8. Statistical analysis and data visualization were done in GraphPad Prism 8. 
Calculation of the MI75 
The MI75 was calculated using the two concentrations (conc) were the MI score 
(MI) is just below (b) and just above (a) the MI score of 0.75. As approximation, a 
linear relationship was assumed allowing the use of the following equation:  
MI75 = log10 (𝑐𝑜𝑛𝑐𝑏 +
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